A Phase 2 Study to Assess the Effect of a Repeated Dose of XF-73 Nasal Gel on the Microbiological Burden of Commensal Staphylococcus Aureus Nasal Carriage in Surgical Patients at Risk of Post-operative Staphylococcal Infections
Phase: PHASE2
Conditions: Staphylococcal Infections, Surgical Site Infection
Sponsor: Destiny Pharma Plc

CLINICAL STUDY PROTOCOL 
A Phase 2 Study to Assess the Effect of a Repeated Dose of Exeporfinium Chloride (XF-
73) Nasal Gel on the Microbiological Burden of Commensal Staphylococcus aureus
Nasal Carriage in Surgical Patients at Risk of Post-Operative Staphylococcal Infections.
Protocol Number: 
XF-73B07 
Investigational Medicinal Product: 
Exeporfinium chloride (XF-73) 
Indication: 
Prevention of post-operative 
staphylococcal infections 
Phase: 
2 
Sponsor: 
Destiny Pharma plc 
Sussex Innovation Centre 
Science Park Square,  
Falmer 
Brighton, BN1 9SB 
United Kingdom 
Sponsor Chief Medical Officer: 
IND Number: 
109303 
Protocol Version and Date: 
Version 2.1, 04 Jun 2020 
The study will be conducted according to the protocol and in compliance with versions of 
Good Clinical Practice (GCP), the Declaration of Helsinki, and other applicable 
regulatory requirements in effect during the time of the conduct of the study. 
This document contains confidential information of Destiny Pharma plc 
Do not copy or distribute without written permission from the Destiny Pharma plc. 
CONFIDENTIAL 
NCT03915470

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
2 
SPONSOR SIGNATURE PAGE 
 
Declaration of Sponsor or Responsible Medical Officer 
 
Title:  
A Phase 2 Study to Assess the Effect of a Repeated Dose of Exeporfinium Chloride (XF-73) 
Nasal Gel on the Microbiological Burden of Commensal Staphylococcus aureus Nasal Carriage 
in Surgical Patients at Risk of Post-Operative Staphylococcal Infections. 
 
This study protocol was subjected to critical review. The information it contains is consistent 
with current knowledge of the risks and benefits of the investigational product, as well as with 
the moral, ethical and scientific principles governing clinical research as set out in the current 
version of the Declaration of Helsinki (Brazil 2013), and the guidelines on Good Clinical 
Practice. 
 
 
 
_____________________________________ 
_____________________ 
 
Date 
Chief Medical Officer 
Destiny Pharma plc 
 
 
_____________________________________ 
_____________________ 
 
Date 
Director of Clinical Projects 
Destiny Pharma plc 
 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
3 
PRINCIPAL INVESTIGATOR SIGNATURE PAGE 
 
Title:  
A Phase 2 Study to Assess the Effect of a Repeated Dose of Exeporfinium Chloride (XF-73) 
Nasal Gel on the Microbiological Burden of Commensal Staphylococcus aureus Nasal Carriage 
in Surgical Patients at Risk of Post-Operative Staphylococcal Infections. 
 
I have read and understood all sections of the protocol. 
I agree to supervise all aspects of the protocol and to conduct the clinical investigation in 
accordance with the final protocol, the International Conference on Harmonisation Tripartite 
Guideline: Good Clinical Practice E6 (R2) and all applicable government regulations. I will not 
make changes to the protocol before consulting with Destiny Pharma plc or implement protocol 
changes without independent ethics committee approval except to eliminate an immediate risk to 
subjects. I agree to administer study treatment only to subjects under my personal supervision or 
the supervision of a sub-Investigator. 
I will not supply the investigational product to any person not authorized to receive it. 
Confidentiality will be protected. Subject identity will not be disclosed to third parties or appear 
in any study reports or publications. 
I will not disclose information regarding this clinical investigation or publish results of the 
investigation without authorization from Destiny Pharma plc. 
 
 
 
_____________________________________ 
_____________________ 
Signature 
Date 
 
 
_____________________________________ 
Print Name (block capitals) 
 
 
_____________________________________ 
Site Number, Name and Address (block capitals) 
 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
4 
1 
PROTOCOL SYNOPSIS 
Title: 
A Phase 2 Study to Assess the Effect of Repeated Dose of Exeporfinium 
Chloride (XF-73) Nasal Gel on the Microbiological Burden of Commensal 
Staphylococcus aureus Nasal Carriage in Surgical Patients at Risk of Post-
Operative Staphylococcal Infections. 
IND Number: 
109303 
Protocol Number: 
XF-73B07 
Phase: 
2 
Sponsor: 
Destiny Pharma plc 
Chief Medical Officer: 
 
Objectives and Endpoints: 
Primary Objective 
Endpoint 
To demonstrate the efficacy of a 
0.2% XF-73 nasal gel in reducing 
the microbiological burden of nasal 
S. aureus measured as change in 
colony forming units (CFU) per 
millilitre (mL) from baseline to 
immediately prior to surgery in a 
patient population at risk of post-
operative staphylococcal infection 
Change in S. aureus log CFU/mL 
from baseline to pre-surgery 
 
Secondary Objectives will 
include 
Endpoint 
To determine the effect of a 0.2% 
XF-73 nasal gel on S. aureus nasal 
burden from baseline to pre-
surgery and from baseline to 
immediately post-surgery 
measured as area under the curve 
(AUC) of S. aureus log CFUs/mL 
over time. 
• Difference in AUC of S. aureus 
log CFU/mL from baseline to 
pre-surgery. 
• Difference in AUC of S. aureus 
log CFU/mL from baseline to 
immediately post-surgery 
To determine the effect of a 0.2% 
XF-73 nasal gel on S. aureus nasal 
burden measured as CFUs/mL in 
follow-up after last administration. 
• Change in S. aureus log 
CFU/mL from immediately 
after surgery to 48 hours after 
surgery 
• Change in S. aureus log 
CFU/mL from immediately 
after surgery to 7 days after 
surgery 
To explore the efficacy of XF-73 
in reducing the burden of S. aureus 
carriage at the patient level. 
• Percentage of patients reaching 
a specific reduction in S. aureus 
carriage prior to surgery, 
immediately post-surgery and 
on Day 6 ± 24hrs. 
To assess the effect of XF-73 on 
S. aureus nasal carriage in the 
prevention of post-operative 
• Difference in the incidence of 
staphylococcal post-operative 
infections during the 30-day 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
5 
staphylococcal infections (surgical 
site infection, blood stream 
infections, and others) during the 
30 days post-surgery (90 days in 
the case of a foreign implant).  
period after surgery (90 days in 
the case of foreign implant) 
To describe the safety and 
tolerability of multiple 
administrations of a 0.2% XF-73 
nasal gel in a population of 
surgical patients at risk of post-
operative staphylococcal 
infections. 
• Incidence of treatment-
emergent adverse events from 
the first dose of study 
medication to 7 days after last 
dose of study medication.  
• Changes in vital signs, safety 
clinical laboratory assessments, 
nasal examination, and brief 
smell identification test (B-
SIT). 
 
Exploratory Objective 
Endpoint 
To describe the use of post-
operative anti-staphylococcal 
antibiotics, except those provided 
for prophylaxis as local standard of 
care (SOC), during the 30-day 
post-surgery period (90 days in the 
case of an object implant) reported 
separately 
• Reason for post-operative 
prescription of anti-
staphylococcal antibiotics 
during the 30-day post-
operative period (90 days post-
surgery in the case of an object 
implant) 
Design: 
This is a Phase 2, multi-centre, randomized, double-blind, parallel, 
placebo-controlled study conducted in patients undergoing surgical 
procedures at risk of post-operative staphylococcal infections.  
Study Population: 
Patients undergoing surgical procedures at risk of post-operative 
staphylococcal infections. 
Inclusion Criteria: 
Individuals who meet all of the following criteria are eligible to participate 
in the study. 
1. Male or female patients between 18 and 75 years of age. 
2. Patients who are confirmed nasal S. aureus carriers by PCR screen 
assay, and due to undergo a surgical procedure associated with risk of 
post-operative staphylococcal infections. 
3. Patients who are willing to provide written informed consent. 
4. Patients who are willing and able (as per Investigator judgement) to 
complete all protocol specified visits and assessments. 
5. Woman of childbearing potential* with a negative urine pregnancy test 
(sensitive to 25 IU human chorionic gonadotropin [hCG]).  
 
* Women of childbearing potential are defined as those women between 
menarche and menopause who have not undergone permanent sterilisation. 
Permanent sterilisation methods include hysterectomy, bilateral 
salpingectomy, and bilateral oophorectomy. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
6 
Exclusion Criteria: 
Individuals who meet any of the following criteria are not eligible to 
participate in the study. 
1. Pregnancy (current) currently lactating. 
2. Uncontrolled acute or chronic illness (as determined by the 
Investigator) in addition to those requiring the planned surgical 
intervention. 
3. History of atopy, allergic reaction, or hypersensitivity to the study 
mediation or its components. 
4. Current upper respiratory tract infection, cold or influenza with 
significant nasal symptoms that might impact on the patient’s ability to 
comply with the gel application procedure. 
5. History of photosensitivity. 
6. Family history of porphyria. 
7. Use of intra-nasal, topical or systemic antibiotics or anti-infectives 
within the last 4 weeks before screening. (Patients who screen positive 
for nasal carriage of S. aureus and receive topical or systemic 
antibiotics or anti-infectives which are not part of their prophylactic 
peri-operative SOC between screening and first dose of IMP will be 
excluded from the study.) The use of intra-nasal antibiotics or anti-
infectives other than the study medication prior to surgery is not 
allowed. 
8. Use of other prescribed or over-the-counter nasal medication in the last 
14 days or oral decongestants in the last 7 days before first 
administration of study drug. 
9. Participation in a clinical trial within the last 12 weeks before first 
administration of study drug. 
10. Contemporaneous clinically significant abnormalities in vital signs or 
laboratory analyses reported within 14 days prior to randomization 
which in the opinion of the Investigator would preclude from the safety 
assessment of the medication under study. 
11. Nasal polyps or significant anatomical or other nasal abnormality that 
would prevent from appropriate administration of the study treatment 
or represent an excessive risk for the patient’s participation. 
12. History of nasal surgery including cauterization. 
13. A recent history of frequent epistaxis and/or an episode of epistaxis 
within 3 months of the planned surgery. 
14. Use of in-situ nasal jewellery or existence of open nasal piercings. 
Number of Patients: 
It is planned that approximately 125 patients will need to be recruited in 
order to have around 80 patients with sufficient burden of S. aureus nasal 
carriage which will allow for the detection of an effect of XF-73 nasal gel 
over placebo.  
Countries/Number of 
Sites: 
USA (~ 10 sites), Georgia (~10 sites), Serbia (~5) 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
7 
Investigational Medicinal 
Product: 
Patients will be randomised in a double-blind manner to either the active or 
placebo arm. The active and placebo study drugs used in the study are as 
follows: 
0.2% w/w XF-73 Nasal Gel (0.3 ml nasal gel equating to 0.6 mg XF-73 per 
naris)  
Placebo to Match XF-73 Nasal Gel (0.3 ml nasal gel per naris) 
Duration of Participation: 
The study duration will be either up to 6 or 12 weeks for each individual 
(from screening to last post-study follow-up visit at either 30 or 90 days). 
The overall duration of the study will be approximately 15 months starting 
Q3 2019 to Q4 2020 
Criteria for Evaluation: 
 
Efficacy Assessments: 
• 
Measurement of S. aureus CFU/mL 
• 
Incidence of post-operative staphylococcal infections 
Safety Assessments: 
• 
Incidence of TEAEs  
• 
Clinical laboratory parameters 
• 
Vital signs 
• 
Physical examinations 
• 
Nasal examination 
• 
Brief Smell identification test (B-SIT). 
Concomitant Medication: 
At randomization, patients will be asked what medications they have taken 
during the last 30 days. At each subsequent study visit, patients will be 
asked what concomitant medications they are currently taking. Special 
attention will be placed in recording the concomitant use of anti-infectives 
and antibiotics. 
The use of intra-nasal antibiotics or anti-infectives other than study 
medication prior to surgery is not allowed. 
The use of skin decolonization products (e.g. chlorhexidine) and systemic 
perioperative prophylactic antibiotics (e.g. intravenous vancomycin) as part 
of the SOC will be recorded.  

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
8 
Statistical Methods: 
A Statistical Analysis Plan (SAP) describing the planned final analysis in 
detail with tables, figures and listings templates will be developed as a 
separate document 
Primary analysis will be on the endpoint of change in log10 CFU from 
baseline to pre-surgery using an analysis of covariance (ANCOVA) model 
including baseline CFU as a covariate. A similar analysis will also be 
performed for the endpoint of change from baseline to the post-surgery 
measurement. 
Secondary efficacy analyses will include; 
• 
Change in log10 CFU from baseline to post-surgery using an ANCOVA 
model including baseline CFU as a covariate. 
• 
A log10 AUC for CFUs will also be undertaken utilising data for all 
time points up until the pre-surgery assessment. This analysis of log10 
AUC CFUs will also including baseline log10 CFU as a covariate. 
• 
A log10 AUC for CFUs will also be undertaken utilising data for all 
time points up until the post-surgery assessment. This analysis of log10 
AUC CFUs will also including baseline log10 CFU as a covariate. 
• 
Percentage of patients reaching a specific reduction in S. aureus 
carriage prior to surgery, immediately post-surgery and on Day 6 ± 
24hrs. 
• 
Proportion of patients with nasal carriage below a set value (value 
TBD) 
• 
Summary of data for nasal carriage according to SQS along with an 
analysis of proportional odds. 
• 
Summary of the proportion of patients with a 2-log drop (TBD) 
All available data from patients in the Safety Population will be included in 
the assessment of safety and tolerability. All safety and tolerability data will 
be listed and summarised by treatment group using appropriate descriptive 
statistics. Formal statistical comparisons between the different treatment 
groups will not be conducted. 
All AEs will be coded using the MedDRA terminology. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
9 
Table 1.1: 
Schedule of Assessments 
Assessment 
Screening 
Visit 
Randomisation 
Visit 
Treatment Period 
Follow-up Period 
Study Day 
Day -14 
to  
Day -1* 
Day -10 to 
Day -1* 
Day -1 to Day 0 
48h ± 24h 
post 
wound 
closure 
Day 6± 
24h 
Day 30 
(and 
Day 90) a 
Dose 1 
Dose 2 
Dose 3 
Dose 4 
Dose 5 
Screening consent 
X 
 
 
 
 
 
 
 
 
 
Nasal Swab for 
S. aureus 
(quantitative and 
rapid screen k)  
X k 
 
Xi 
 
X i 
X i 
X i 
X 
X 
 
Study consent 
 
X 
 
 
 
 
 
 
 
 
Inclusion/Exclusion 
Criteria  
 
X 
X 
 
 
 
 
 
 
 
Demographics 
 
X 
 
 
 
 
 
 
 
 
Medical /Surgical 
History  
 
X 
X m 
 
 
 
 
 
 
 
Prior Medication 
History 
 
X 
X m 
 
 
 
 
 
 
 
Physical 
Examination b 
 
X 
X 
 
 
 
 
X 
X 
 
Examination of 
Nose and Nasal 
Passages by ENT c 
 
X c 
X c 
 
 
 
 
X 
 
 
Vital Signs d 
 
Xn 
 
 
 
 
X 
X 
X 
 
Clinical Chemistry 
and Haematology e 
 
Xn 
 
 
 
 
X (Post 
dose) 
X 
X 
 
Urinalysis f 
 
X 
 
 
 
 
X (Post 
dose) 
X 
 
 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
10 
Table 1.1: 
Schedule of Assessments 
Assessment 
Screening 
Visit 
Randomisation 
Visit 
Treatment Period 
Follow-up Period 
Study Day 
Day -14 
to  
Day -1* 
Day -10 to 
Day -1* 
Day -1 to Day 0 
48h ± 24h 
post 
wound 
closure 
Day 6± 
24h 
Day 30 
(and 
Day 90) a 
Dose 1 
Dose 2 
Dose 3 
Dose 4 
Dose 5 
Pregnancy Test 
 
X 
 
 
 
 
 
 
X 
 
Record standard of 
care in skin 
decontamination and 
peri-operative 
prophylactic 
regimen 
 
X 
X 
X 
X 
X 
X 
X 
 
 
Record blood 
glucose levels and 
temperature during 
surgery j 
 
 
 
 
 
X 
X 
 
 
 
Brief Smell 
Identification Test 
 
X g 
X g 
 
 
 
 
 
X 
 
Adverse Events  
 
Xl 
X 
X 
X 
X 
X 
X 
X 
 
Concomitant 
medication 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Randomisation  
 
X g 
X g 
 
 
 
 
 
 
 
Study Drug 
Administration h 
 
 
X 
X 
X 
X 
X 
 
 
 
Record 
staphylococcal 
infections and use of 
antibiotics 
 
 
 
 
 
 
 
X 
X 
X 
ENT=Ear, Nose, and Throat specialist 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
11 
*)  All screening and randomisation activity to be completed ahead of Dose 1 
a) The Day 90 Follow-up Visit is for patients who have had a foreign implant during surgery. 
b) A complete physical examination, including height and weight, (skin; head, eyes, ears, nose, and throat; lymph nodes; heart, lungs, and abdomen; extremities 
and joints; and neurological examination, but no breast, genital, or rectal examinations) will be done at the Randomisation Visit OR before nasal swab prior 
to dose 1. Brief symptom-driven physical examinations (including the nose and nasal passages) will be done at other visits.  
c) Nasal examination by ENT specialist at randomisation OR before nasal swab prior to dose 1, and again at 48+/-24h (post wound closure nasal swab). Nasal 
examination by ENT specialist at other timepoints if investigator mandated (i.e. symptoms/signs directed) 
d) Vital signs including blood pressure and heart rate, taken in supine position.  
e) Clinical safety lab tests will consist of the following: Haematology: Complete Blood Count (CBC), including Red blood cell (RBC) count, Haemoglobin, 
Haematocrit, RBC indices and red cell diameter width (RDW), white blood cell (WBC) total and differential count, and Platelet count; Serum Chemistry: 
Serum Sodium, Potassium, Carbon dioxide (CO2) (bicarbonate), Chloride, Blood urea nitrogen (BUN), Creatinine, Glucose (Screening), Glucose 
(Admission, Discharge and Follow up); record the time the patient last ate for all glucose levels, Calcium, Magnesium, Phosphate, Uric acid, Alanine 
aminotransferase (ALT), Aspartate aminotransferase (AST), Total bilirubin, Alkaline phosphatase, Total protein, and Albumin 
f) 
Urinalysis dip-stick for at least test (pH, spec gravity, proteins, glucose, ketones, bilirubin, nitrites, WBC, blood). If there are abnormal findings samples will 
be sent for microscopic examination Microbiological testing to undertaken at the Investigators decision 
g) Baseline Brief Smell Identification Test and Randomization may occur between Day -10 and Day -1 prior to Dose 1. 
h)  XF-73 or placebo will be administered 4 times into each nostril prior to surgery and then a single application immediately after wound closure. 
i) 
Nasal swabs are taken within 1 hour before the corresponding dose. 
j) 
The number of total glucose/core temperature determinations between admission to hospital for surgery and the period 48±24hours after surgery is 
determined by how many are over 200 mg/dL for glucose or below 35.5 °Celsius for temperature. 
k) Only rapid screen nasal swab required at Screening. No quantitative testing will be performed. 
l)     Record AEs that according to investigator’s judgement are related with the screening procedures. 
m)   If changes from randomization visit. 
n)  Standard of care or study mandated vital signs or laboratory analyses reported within 14 days prior to randomization should be used to determine 
inclusion/exclusion criteria. 
 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
12 
2 
TABLE OF CONTENTS 
1 
PROTOCOL SYNOPSIS ...................................................................................... 4 
2 
TABLE OF CONTENTS .................................................................................... 12 
3 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS .................. 16 
4 
INTRODUCTION................................................................................................ 19 
4.1 
Background ...................................................................................................... 19 
4.2 
Rationale .......................................................................................................... 21 
4.3 
Risk-Benefit Assessment ................................................................................. 21 
5 
STUDY OBJECTIVES AND ENDPOINTS ...................................................... 23 
5.1 
Primary Objective and Endpoint .................................................................. 23 
5.2 
Secondary Objectives and Endpoint ............................................................. 23 
5.3 
Exploratory Objective and Endpoint ............................................................ 24 
6 
OVERALL DESIGN AND PLAN OF THE STUDY ....................................... 25 
6.1 
Overview .......................................................................................................... 25 
6.2 
Discussion of Study Design ............................................................................. 27 
6.2.1 
Rationale for the Dosage of XF-73 ...................................................... 27 
6.2.2 
Use of Placebo ..................................................................................... 29 
7 
STUDY POPULATION ...................................................................................... 31 
7.1 
Inclusion Criteria ............................................................................................ 31 
7.2 
Exclusion Criteria ........................................................................................... 31 
7.3 
Patient Withdrawal ......................................................................................... 32 
7.3.1 
Reasons for Withdrawal ....................................................................... 32 
7.3.2 
Replacement of Patients ....................................................................... 32 
7.4 
Patient Identification and Randomization .................................................... 32 
7.5 
Stopping and Discontinuation ........................................................................ 33 
8 
STUDY DRUG ..................................................................................................... 34 
8.1 
Identity of Study Drugs .................................................................................. 34 
8.1.1 
0.2% w/w XF-73 Nasal Gel ................................................................. 34 
8.1.2 
Placebo to Match XF-73 Nasal Gel ..................................................... 34 
8.2 
Maintenance of the Blind ................................................................................ 35 
8.3 
Administration of Study Drug ....................................................................... 35 
8.4 
Packaging, Labelling and Storage ................................................................. 36 
8.5 
Drug Accountability ........................................................................................ 36 
8.6 
Compliance ...................................................................................................... 37 
8.7 
Concomitant Medications ............................................................................... 37 
8.8 
Treatment of Overdose ................................................................................... 37 
9 
PARAMETERS AND METHODS OF ASSESSMENT .................................. 38 
9.1 
Microbiological Assessments .......................................................................... 38 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
13 
9.1.1 
Screening.............................................................................................. 38 
9.1.2 
Treatment and Follow-up Periods ........................................................ 38 
9.1.3 
Microbiological Specimen Collection and Culture for S. aureus ........ 39 
9.2 
Efficacy Parameters ........................................................................................ 39 
9.3 
Safety Parameters ........................................................................................... 39 
9.3.1 
Adverse Events .................................................................................... 39 
9.3.1.1 
Definitions ...................................................................................... 39 
9.3.1.2 
Recording Adverse Events ............................................................. 41 
9.3.1.3 
Responsibilities of the Investigator ................................................ 42 
9.3.1.4 
Responsibilities of the Sponsor ...................................................... 42 
9.3.1.5 
Evaluation of Adverse Events ........................................................ 43 
9.3.1.6 
Notifying of Adverse Events ........................................................... 43 
9.3.2 
Pregnancy ............................................................................................. 44 
9.3.3 
Laboratory Parameters ......................................................................... 44 
9.3.4 
Vital Signs ............................................................................................ 45 
9.3.5 
Physical Examinations ......................................................................... 45 
9.3.6 
Assessment of Nose, Nasal Passages, and Sense of Smell .................. 45 
9.3.6.1 
Nasal Examination by ENT specialist............................................ 45 
9.3.6.2 
Brief Smell Identification Test™ ................................................... 45 
10 
STUDY CONDUCT ............................................................................................. 47 
10.1 
Observations by Visit ...................................................................................... 47 
10.1.1 
Screening Visit (Day -14 to Day -1) .................................................... 47 
10.1.2 
Randomization Visit (Day -10 to Day -1) ............................................ 47 
10.1.3 
Treatment Period (Days -1 to Day 0) ................................................... 48 
10.1.3.1 
First dose visit (Day -1) ................................................................. 48 
10.1.3.2 
Second dose visit (Day -1) ............................................................. 49 
10.1.3.3 
Third dose visit (Day 0) ................................................................. 49 
10.1.3.4 
Fourth dose visit (Day 0) ............................................................... 49 
10.1.3.5 
Fifth dose visit (Day 0) .................................................................. 49 
10.1.4 
Follow-up Period ................................................................................. 50 
10.1.4.1 
Post-surgical visit (48h ± 24h post closure of surgical incisions). 50 
10.1.4.2 
Follow Up (Day 6 (± 24 hours) ..................................................... 50 
10.1.4.3 
Follow-up (Day 30)........................................................................ 51 
10.1.4.4 
Follow-up Day 90 (Only if object implant in surgery) .................. 51 
11 
STATISTICAL METHODS ............................................................................... 52 
11.1 
Disposition of Patients ..................................................................................... 52 
11.2 
Protocol Deviations ......................................................................................... 52 
11.3 
Analysis Populations ....................................................................................... 52 
11.3.1 
All Enrolled Patients ............................................................................ 52 
11.3.2 
Safety Population ................................................................................. 52 
11.3.3 
Intent-To-Treat Population .................................................................. 52 
11.3.4 
Modified Intent-To-Treat Population .................................................. 52 
11.3.5 
Microbiological Intent-To-Treat Population........................................ 52 
11.3.6 
Per-protocol Population ....................................................................... 53 
11.4 
General Considerations .................................................................................. 53 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
14 
11.5 
Demographics, Baseline Characteristics and Concomitant Medications .. 53 
11.6 
Treatment Compliance ................................................................................... 53 
11.7 
Efficacy Analyses ............................................................................................. 53 
11.8 
Safety Analyses ................................................................................................ 54 
11.9 
Interim Analyses .............................................................................................. 54 
11.10 Determination of Sample Size ........................................................................ 55 
12 
DATA MANAGEMENT ..................................................................................... 56 
12.1 
Data Collection ................................................................................................ 56 
12.2 
Data Correction ............................................................................................... 56 
12.3 
Data Handling .................................................................................................. 56 
12.3.1 
Deviations from the Protocol ............................................................... 56 
12.4 
Data Quality Assurance .................................................................................. 57 
13 
QUALITY CONTROL AND QUALITY ASSURANCE ................................. 58 
13.1 
Study Initiation Activities ............................................................................... 58 
13.2 
Training of Site Staff ....................................................................................... 58 
13.3 
Documentation and Filing .............................................................................. 58 
13.3.1 
eCRF System ....................................................................................... 58 
13.3.2 
List of Patients (patient identification log) .......................................... 58 
13.3.3 
Source Data .......................................................................................... 58 
13.3.4 
Investigator Site File / Regulatory Binder ........................................... 59 
13.4 
Monitoring ....................................................................................................... 59 
13.5 
Audits and Inspections .................................................................................... 59 
14 
ETHICAL, LEGAL AND ADMINISTRATIVE ASPECTS ........................... 60 
14.1 
Good Clinical Practice .................................................................................... 60 
14.2 
Informed Consent ............................................................................................ 60 
14.3 
Protocol Approval and Amendment .............................................................. 60 
14.4 
Archiving Study Records ................................................................................ 60 
14.5 
Premature Termination of the Study ............................................................ 61 
14.6 
Confidentiality ................................................................................................. 61 
14.7 
Future Use of Stored Specimens .................................................................... 61 
14.8 
Liability and Insurance ................................................................................... 61 
14.9 
Publication Policy ............................................................................................ 62 
15 
REFERENCE LIST ............................................................................................. 63 
16 
APPENDICES ...................................................................................................... 66 
16.1 
List of Organizations Involved in the Study ................................................. 66 
 
Tables in Text 
Table 1.1: Schedule of Assessments .................................................................................... 9 
Table 6.1: Analysis of Direct Plating Score Response Rate (ITT Population) – Study XF73-
B03 28 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
15 
Table 6.2: Response Rate (SQSA Score = negative/zero) (PD Population; Baseline 
Responders Removed) – Study DMID11-0007 .......................................................... 29 
Table 8.1: Components of 0.2% w/w XF-73 Nasal Gel ..................................................... 34 
Table 8.2: Components of Placebo to Match XF-73 Nasal Gel ......................................... 35 
Table 9.1: Laboratory Parameters ...................................................................................... 44 
 
Figures in Text 
Figure 6.1: 
Study Design ........................................................................................ 26 
 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
16 
3 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
 
Abbreviation 
Definition 
AE 
Adverse event 
ALT 
Alanine aminotransferase 
ANCOVA 
Analysis of covariance 
AST 
Aspartate aminotransferase 
AUC 
Area under the curve 
BDRM 
Blinded data review meeting 
BP 
Blood pressure 
B-SIT 
Brief Smell Identification Test™ 
BUN 
Blood urea nitrogen 
CFR 
Code of Federal Regulations 
CFU 
Colony forming units 
CHRS 
Cardinal Health Research Service 
CO2 
Carbon Dioxide 
CRA 
Clinical Research Associate 
CSR 
Clinical study report 
DNA 
Deoxyribonucleic acid 
eCRF 
electronic Case report form 
EDC 
Electronic data capture 
ENT 
Ear, Nose and Throat specialist 
FD&C 
Food, Drug & Cosmetic 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
GMP 
Good Manufacturing Practice 
hCG 
Human chorionic gonadotropin 
HDPE 
High Density Polyethylene 
HIV 
Human immunodeficiency virus 
HPC 
Hydroxypropyl cellulose 
IB 
Investigator’s Brochure 
ICF 
Informed consent form 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
17 
Abbreviation 
Definition 
ICH 
International Council for Harmonisation 
IDMC 
Independent Data Monitoring Committee 
IDSA 
Infectious Disease Society of America 
IEC 
Independent Ethics Committee 
IN 
Intranasal 
IP 
Investigational product 
IRB 
Institutional Review Board 
IRT 
Interactive Response Technology 
ISF 
Investigational Site File 
ITT 
Intent-to-treat 
JP 
Japanese Pharmacopoeia 
MedDRA 
Medical Dictionary for Regulatory Activities 
MIC 
Minimum inhibitory concentration 
MRSA 
Methicillin-resistant S. aureus 
MSSA 
Methicillin-sensitive S. aureus 
NF 
National Formulary 
NHSN 
National Healthcare Safety Network 
PCR 
Polymerase chain reaction 
Ph Eur 
European Pharmacopoeia 
PP 
Per-protocol 
QS 
Quantity sufficient 
RNA 
Ribonucleic acid 
S. aureus 
Staphylococcus aureus 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SD 
Standard deviation 
SHEA 
The Society for Healthcare Epidemiology for America 
SIS 
Surgical Infection Society 
SOC 
Standard of care 
SSI 
Surgical site infection 
SUSAR 
Suspected unexpected serious adverse reaction 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
18 
Abbreviation 
Definition 
TBD 
To be determined 
TEAE 
Treatment-emergent adverse event 
US 
United States 
USP 
United States Pharmacopoeia 
WHO 
World Health Organization 
 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
19 
4 
INTRODUCTION 
4.1 
Background 
Staphylococcus aureus (S. aureus) and specially the more antibiotic resistant strain, Methicillin-
Resistant S. aureus (MRSA), is a common causative organism of nosocomial infections in 
hospitals across the world8. It was estimated that 1% of all hospitalized patients in the United 
States (US) suffered from S. aureus infections, equating to nearly 400,000 patients19, at an 
estimated cost of $14.5 billion. Amongst nosocomial infections caused by S. aureus (including 
MRSA), Surgical Site Infections (SSIs) are a major infectious entity and are a cause of 
significant morbidity and mortality22,23. The prevalence of MRSA nosocomial infections in the 
US ranges from 42.6% to 52.0% depending of the site of the nosocomial infection23. The most 
recent data from the National Healthcare Safety Network (NHSN) in the US showed that despite 
recent efforts, 42.6% of all reported S. aureus surgical site infections were due to MRSA23. At 
least 80% of such infections are caused by the patients’ own bacteria9-11. S. aureus can colonize 
several body sites - nose, axillae, groin and throat - although the anterior nares are the preferred 
ecologic niche and are identified as the most frequent site of carriage11-13, with 25 to 35%14 of the 
population being colonized at any given time. S. aureus carriers are at a higher risk of 
staphylococcal infections after invasive medical or surgical procedures than non-carriers, having 
been estimated to be 2 to 10 times more likely to develop surgical-site/intravenous catheter 
infections15-18. Specifically, S. aureus nasal carriage has been identified as a risk factor for the 
development of infections in orthopaedic, thoracic and general surgery as summarized in a 
review by Wertheim et al (2005)11. 
Standard infection control measures, including hand-washing by staff with antiseptic detergents 
or 70% alcohol, ward cleaning, disinfecting equipment, correct handling of clinical waste, etc are 
important for limiting MRSA cross-infection. However, body decolonization procedures 
(typically nasal decolonization and additional body washes) have been adopted or recommended 
for at-risk patients in many settings25. 
In 2010, Bode et al reported the results of a randomized, double-blind, placebo-controlled study 
investigating nasal and body decolonization and concluded that hospital-acquired infections with 
S. aureus could be prevented by initiating decolonization treatment (nasal and body) 
immediately after admission of surgical patients20. In a commentary on this study, Bertrand et al 
also concluded that pre-emptive S. aureus decolonization should be used in surgery with a high 
risk of S. aureus infection such as open-heart surgery and orthopaedic or neurosurgical implant 
procedures9. In their review of published data on decolonization therapy from 2008 to 2010, 
Hebert and Robicsek concluded that decolonization therapy was likely to be an effective tool for 
reducing surgical infection in cardiac and orthopaedic patients21. Kim et al have reported a study 
in 7,019 orthopaedic surgical patients, concluding that a program of identification and 
eradication of both MRSA and methicillin-sensitive S. aureus (MSSA) carriage with intranasal 
mupirocin and chlorhexidine showers can lead to significant reductions in post-operative rates of 
surgical site infection5. 
In February 2013, a consensus involving the Surgical Infection Society (SIS), Infectious Disease 
Society of America (IDSA) and The Society for Healthcare Epidemiology for America (SHEA), 
published guidelines which recommend the use of nasal decolonization of all S. aureus in 
cardiovascular and orthopaedic surgery26. They also discussed the risks in other clean surgeries 
where there was not the level of proof to make a formal recommendation yet. As the only 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
20 
approved agent for nasal decolonization, mupirocin is cited, with caveats over widespread use, 
compliance and awareness of potential resistance. The SIS guidelines26 are likely to increase the 
number of centres employing S. aureus decolonization in the surgeries identified, but this may be 
affected by the limitations of mupirocin in respect of treatment duration, compliance, concerns 
over resistance and logistical difficulties associated with pre-admission screening. 
Despite these recommendations, existing product approvals do not explicitly exemplify the use 
of prophylactic intranasal (IN) antibiotics by surgical patients. In the US, Mupirocin 
(Bactroban®) is indicated for MRSA decolonization during institutional outbreaks; in Europe the 
indication is worded: ‘the elimination of nasal carriage of staphylococci, including MRSA’. In 
fact, S. aureus nasal decolonisation is not universally accepted practice and if practiced it is not 
done in a standard manner, but with a variety of products and dosing regimens for each product 
as none of these are approved for the intended indication. 
Exeporfinium chloride (XF-73) is a dicationic porphyrin derivative having potent bactericidal 
properties with a novel mode of action. XF-73 is being developed as a viscous dermal gel for the 
decolonization of S. aureus in the anterior nares (nasal cavity) to prevent post-operative 
staphylococcal infections.  
XF-73 has been investigated against a panel of 101 Gram-positive and Gram-negative organisms 
selected for susceptibility and cross-resistance testing2. The panel comprised 65 Gram-positive 
isolates (56 aerobic and 9 anaerobic) and 36 Gram-negative isolates (31 aerobic and 
5 anaerobic). XF-73 demonstrated excellent bactericidal activity against all Gram-positive strains 
tested regardless of species, phenotype or genotype, with minimum inhibitory concentrations 
(MICs) of 0.25 to 4 mg/L. The antibacterial activity against Gram-negative species was lower, 
with MICs of 1 mg/L to > 64 mg/L. The study indicated that XF-73 is rapidly bactericidal 
against S. aureus, including methicillin-resistant strains (including USA300) 2 (Study R14). 
Exposure of bacteria to XF-73 resulted in an observed loss of membrane potential within 
1 minute, followed by efflux of small molecular weight molecules, ATP and potassium; 
>99.99% of S. aureus are killed within 5 minutes1. The mode of action is thus focused on the 
bacterial cell membrane. Cell death is not accompanied by lysis of the cells, as observed by 
electron microscopy (Study R39) or resulting in efflux of large molecular weight components 
(DNA, RNA, proteins) 1. 
A multistep study, in which MRSA was passaged 55 times, showed that XF-73 had a very low 
potential for inducing resistance over the 55 passages. The MIC values showed no more than a 
4-fold increase over the starting MIC and the accepted threshold for resistance (≥ 8-fold increase 
in MIC) was not reached3.  
The speed of onset of anti-staphylococcal activity of XF-73 has also been observed during 
clinical studies, in which the level of S. aureus isolated from heavily colonized, stable S. aureus 
carriers was observed to be reduced dramatically after 1 to 3 doses over 1 day. These 
characteristics have supported the targeting of a preferred indication of IN administration to 
prevent post-operative staphylococcal infections. In this setting, the rapidity of action will allow 
for a short treatment course around surgery.  
To date there have been 7 completed clinical studies on XF-73 (5 intranasal and 2 dermal) in 263 
patients, of which 241 received XF-73. In the intranasal (i.n.) studies carried without 
photodymanic therapy, the most common (≥10%) adverse events (AEs) reported with XF-73 gel 
application are headache (11.4%), nasal discomfort (9.0%), and rhinorrhoea (7.8%). Most of the 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
21 
treatment-emergent AEs (TEAEs) associated with nasal gel application from previous studies 
were considered mild to moderate in intensity. Further details can be found in the current version 
of Investigator's Brochure (IB), which contains comprehensive information on the investigational 
product. 
This is a proof-of-concept study which will assess the efficacy and safety of XF-73 in the 
decolonisation of nasal carriers of S. aureus that will undergo a surgical procedure associated 
with risk of post-operative staphylococcal infections.  
4.2 
Rationale 
XF-73 provided as a 2 mg/g nasal gel with 
 is being 
developed for the prevention of post-operative staphylococcal infections. Both microbiological 
and clinical data support the move of XF-73 into this Phase 2 proof-of-concept study to assess 
the safety and microbiological efficacy of XF-73 in reducing the burden of nasal S. aureus before 
surgery in patients who are undergoing procedures at risk of post-operative staphylococcal 
infection, the population for which XF-73 is intended.  
XF-73 possesses anti-bacterial activity in vitro in the 0.5 to 1 mg/L concentration range, against 
S. aureus colonies, including MRSA, as well as for other potentially pathogenic Staphylococci 
spp. This antibacterial activity is rapid and suggests that a short duration of treatment e.g., 24 to 
48 hours will be possible, promoting compliance with the treatment.  
Two Phase 1 studies in human volunteers, who were confirmed nasal carriers of S. aureus, have 
already assessed the safety of XF-73 2 mg/g nasal gel and preliminary efficacy in reducing the 
burden of S. aureus in the nose: study XF-73B03 study with 63 healthy volunteers and study 
DMID11-007 with 56 healthy volunteers. These studies have used different regimens 
concentrations of XF-73 (0.5 mg/g and 2 mg/g) in different regimens (from 1 IN application 
every 12 hours for 2 days to 1 IN application every 8 hours for 1 day and then every 12 hours for 
another 4 days) and have analysed efficacy (burden of nasal S. aureus) in various ways 
(percentage of patients decolonized, evolution of quantitative S. aureus scores and area under the 
curve of quantitative S. aureus scores). Although limited in volunteers’ numbers, both studies 
have shown consistent better responses for the XF-73 2mg/g nasal gel compared to placebo. 
These studies have also allowed to assess the dynamics of nasal burden of S. aureus when 
exposed to XF-73 and inform a dose selection for further development and last but not least, 
these studies have depicted a favourable safety and tolerability profile for XF-73. XF-73 has also 
been assessed for safety up to 5.0 mg/g aqueous solution applied to the shoulder in healthy 
volunteers. These data suggest that XF-73 may also reduce the burden of S. aureus, including 
MRSA, before surgery in patients at risk of post-operative staphylococcal infections.   
In summary, the data from previous studies warrant the move of XF-73 into a further step in its 
development for the prevention of post-operative staphylococcal infections with this Phase 2 
proof-of-concept study where the safety and efficacy of XF-73 to decrease the burden of nasal 
carriage of S. aureus will be studied in actual patients who will undergo a procedure at risk of 
post-operative staphylococcal infections. Please refer to the current IB for further information. 
4.3 
Risk-Benefit Assessment 
The safety of nasal application of XF-73 in concentrations up to 2 mg/g, cumulative doses up to 
13.2 mg and for up to 5 days has already been studied in 172 volunteers. The most common AEs 
reported as related to XF-73 have been nasal discomfort, headache and rhinorrhoea in 17, 14 and 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
22 
14 patients, respectively. These events were mostly mild in intensity, transient and resolved 
spontaneously without sequelae. Post-dose nasal examinations have not revealed erythema or 
increased secretions, so these events seem to be more related with the physical presence and 
sensation of the gel in the nares rather than a physiological interaction with the nasal mucosa; 
though a dose response cannot be fully ruled out.  
Only one suspected unexpected serious adverse reaction (SUSAR), hyposmia, has been reported; 
and has also been the only related serious adverse event so far. This was in study DMID11-007 
and since this report the remaining 21 volunteers were provided a smell test pre- and post- study. 
No signal was detected. 
XF-73 plasma levels have been determined in all studies up to date showing no evidence of 
systemic absorption (assay detection limit 0.2 ng/mL), therefore no systemic toxicity from XF-73 
is expected in this study. Of note, in the studies with XF-73 nasal gel to date, there have been no 
AEs leading to treatment or study discontinuation.  
XF-73 provided as a nasal gel has been shown to be well tolerated in different healthy volunteer 
studies; nevertheless in this Phase 2 study, with patients who will undergo surgery, besides the 
usual safety exams (physical, biochemistry and haematological laboratory tests) a nasal 
examination by an ear nose and throat (ENT) specialist will be performed pre and post-dosing to 
further assess the risks from the contact of XF-73 gel and the nasal mucosa as well as a pre-post-
dosing smell test to address the possible risk of hyposmia as it was seen in study DMID11-007. 
An independent data monitoring committee (IDMC) of experts will be set up which will 
regularly review the safety information from the study as well as the incidence of post-operative 
staphylococcal infections. Should these reach an unexpectedly high level, the IDMC can 
recommend stopping the study. The IDMC charter containing amongst others membership, 
meetings frequency, structure and procedures produced before randomization of the first patient 
will be updated implementing the changes introduced in this version 2.1 of the protocol. 
A benefit cannot be guaranteed, given the early stage of development if XF-73, however it is 
expected that the reduction in nasal burden of S. aureus seen in the healthy volunteers will 
reproduce in patients who participate in this study, which may translate in a reduction in the risk 
of developing post-operative staphylococcal infections. This benefit will be difficult to 
appreciate in this study as the incidence of these infections is low and the number patients to 
enrol very limited. 
In summary, even though a benefit cannot be guaranteed or measured, only expected; the risks 
are limited. Additionally, surveillance measures to reassess benefit-risk during the execution of 
the study such as the nasal examination smell test and an IDMC are in place; so that appropriate 
action can be taken should an unexpected signal arise. The risk-benefit assessment is therefore 
thought to be favourable in this study. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
23 
5 
STUDY OBJECTIVES AND ENDPOINTS 
5.1 
Primary Objective and Endpoint 
Objective 
Endpoint 
To demonstrate the efficacy of a 0.2% XF-73 
nasal gel in reducing the microbiological 
burden of nasal S. aureus measured as change 
in colony forming units (CFU) per mL from 
baseline to immediately prior to surgery in a 
patient population at risk of post-operative 
staphylococcal infection 
• Change in S. aureus log CFU/mL from 
baseline to pre-surgery 
 
5.2 
Secondary Objectives and Endpoint 
Objective 
Endpoint 
To determine the effect of a 0.2% XF-73 nasal 
gel on S. aureus nasal burden from baseline to 
pre-surgery and from baseline to immediately 
post-surgery measured as area under the curve 
(AUC) of S. aureus log CFUs/mL over time. 
• Difference in AUC of S. aureus log 
CFU/mL from baseline to pre-surgery. 
• Difference in AUC of S. aureus log 
CFU/mL from baseline to immediately post-
surgery. 
To determine the efficacy of a 0.2% XF-73 
nasal gel in their effect on S. aureus nasal 
burden measured as CFUs/mL in follow-up 
immediately after surgery, at approximately 
48 hours after surgery and 7 days after surgery. 
• Change in S. aureus log CFU/mL from 
baseline to immediately after surgery 
• Change in S. aureus log CFU/mL from 
baseline to 48 hours after surgery 
• Change in S. aureus log CFU/mL from 
baseline to 7 days after surgery 
To explore the efficacy of XF-73 in reducing 
the burden of S. aureus carriage at the patient 
level. 
• Percentage of patients reaching a specific 
reduction in S. aureus carriage prior to 
surgery, immediately post-surgery and on 
Day 6 ± 24hrs. 
To assess the effect of XF-73 on S. aureus 
nasal carriage in the prevention of post-
operative staphylococcal infections (surgical 
site infections, blood stream infections and 
others) during the 30 days post-surgery 
(90days in the case of a foreign implant).  
• Difference in the incidence of S. aureus 
post-operative infections during the 30-day 
period after surgery (90 days in the case of 
foreign implant) 
To describe the safety and tolerability of 
multiple administrations of a 0.2% XF-73 nasal 
gel in a population of surgical patients at risk 
of post-operative staphylococcal infections. 
• Incidence of TEAEs from the first dose of 
study medication to 7 days post last 
application of study medication 
• Changes in vital signs, safety clinical 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
24 
laboratory assessments, nasal examination, 
and smell identification test. 
 
5.3 
Exploratory Objective and Endpoint 
Objective 
Endpoint 
To describe the use of post-operative anti-
staphylococcal antibiotics, except those 
provided for prophylaxis as local standard of 
care (SOC), during the 30-day post-surgery 
period (90 days in the case of an object 
implant) reported separately. 
• Reason for post-operative prescribed anti 
staphylococcal antibiotic use during the 
30-day post-operative period (90 days in the 
case of an object implant) 
 
 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
25 
6 
OVERALL DESIGN AND PLAN OF THE STUDY 
6.1 
Overview 
This is a Phase 2, multi-centre, randomized, double-blind, parallel, placebo-controlled study of 
multiple applications of a single concentration of XF-73 nasal gel to assess the microbiological 
effect of XF-73 on commensal S. aureus nasal carriage in patients scheduled for surgical 
procedures deemed to be at high risk of post-operative S. aureus infection. The study is divided 
in 4 periods: screening (Days -14 to -1) randomization (Days -10 to -1), treatment (Days -1 and 
0) and follow-up (post-last study dose to Day 30 or Day 90 if an implant is inserted during 
surgery). Day 0 is the calendar day in which surgery takes place. Only patients who test positive 
to S. aureus by a standardized rapid diagnostic test will be enrolled in the study. Approximately 
125 patients will be randomised in a double-blind manner (the investigators and patients are 
blind to the treatment assignment) in a 1:1 ratio to 0.2% w/w XF-73 nasal gel treatment OR 
placebo to match XF-73 nasal gel. 
The study drug, 0.2% w/w XF-73, or matched placebo will be administered 4 times into each 
nostril over 24 hours prior to surgery and then a single application immediately upon closure of 
surgical wound. Additionally, patients may undergo chlorhexidine skin decolonisation ahead of 
surgery and receive perioperative prophylactic systemic antibiotics in accordance with local 
practice. 
In total 7 nasal swabs will be taken: at screening, 3 times prior to surgery (surgery within 
1 hour), post-surgery (right after surgical wound closure), 48 hours post-surgery and 7 days post-
surgery.  
Efficacy will be assessed by S. aureus colonisation from screening to 7 days after surgery as well 
as by incidence of post-operative staphylococcal infections and use of anti-staphylococcal 
antibiotics post-surgery. Safety will be assessed by reported AEs from screening up to Day 6 as 
well as vital signs, physical examination (ENT), clinical laboratory assessments (haematology, 
clinical chemistry, and urinalysis) and Brief-Smell Identification Tests (B-SIT) at different time 
points as reflected in Table 1.1. 
The maximum study duration will be up to 45 or 105 days for each individual (from screening to 
post-study follow-up visit) depending on whether a foreign implant was inserted during surgery.  
An IDMC will be set up which will review the safety information from the study and the 
incidence of post-operative staphylococcal infections. Based on the findings from these 
activities, the IDMC can recommend; 
• Stop the study in case of serious concerns on subject’s safety.   
• Stop the study due to the incidence of post-operative staphylococcal infections. 
• Continue as currently described in the protocol 
• Continue the study with protocol modifications. 
The  IDMC charter containing, amongst other things: membership, meetings frequency, stopping 
criteria, structure and procedures produced before randomization of the first patient will be 
updated implementing the changes introduced in this version 2.1 of the protocol.  
Figure 6.1 presents the study design. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
26 
Figure 6.1: 
Study Design 
 
 
 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
27 
6.2 
Discussion of Study Design 
This is a Phase 2, randomised, double-blind, parallel, placebo-controlled, study of a 
single concentration of XF-73 nasal gel conducted in surgical patients who are at risk of 
post-operative staphylococcal infections. Patients will be randomised in a double-blind 
manner to either the active or placebo arm on a 1:1 basis. 
6.2.1 Rationale for the Dosage of XF-73 
The dosing regimen to be assessed in this study, four 0.3 mL applications in each naris of 
a 2 mg/g XF-73 
 nasal gel 24 hours before surgery and a 5th application right 
after surgery (a cumulative dose of 6 mg of XF-73), is supported by microbiological and 
clinical data from XF-73 Phase 1 studies. Microbiological data showed that XF-73 has a 
rapid antibacterial activity and suggests that a short duration of treatment may be 
possible, facilitating compliance with this treatment.  
In study XF-73B03, 63 healthy volunteers (safety population) who were nasal persistent 
carriers of S. aureus were randomly assigned to receive XF-73 nasal gel (0.5 mg/gr) or 
XF-73 nasal gel (2.0 mg/gr), both with 
, or placebo in each naris every 12 hours 
for 2 days; 27, 12 and 24 volunteers per group respectively. Burden of S. aureus in the 
naris was measured as semiquantitative S. aureus scores during the 2-day treatment 
period and up to discharge (Day 4) and follow-up (up to Day 6).  
The efficacy data for the treatment period showed consistent better responses for the 
2 XF-73 groups than for placebo in different efficacy measures: eradication rates of 
S. aureus from participants’ noses; semiquantitative S. aureus scores; time to first 
clearance and mean differences in AUC. In many instances these differences were 
statistically significant in favour of XF-73. In the efficacy data at discharge (Day 4), on 
the other hand, only the AUC analysis showed statistically significant differences in 
favour of XF-73 groups for the discharge. No differences between study groups were 
detected during the follow-up period (Days 7 and 14). XF-73 was well tolerated at all 
dose levels used in this study.  
Results for eradication of S. aureus during the treatment period (i.e., after 2 doses to each 
naris in the first 24-hour period and after 4 doses to each naris in the first 48-hour period), 
are described in the Table 6.1 below. In summary, for the XF-73 2.0 mg/g group there 
was a 41.7% (10 out of 24, P = 0.0087) clearance of S. aureus carriage at 24 hours after 
2 doses (total dose 2.4 mg of XF-73) and a 37.5% (9 out of 24, P = 0.0965) clearance of 
S. aureus carriage at 48 hours after 4 doses (total dose 4.8 mg of XF-73) over placebo. 
For the XF-73 0.5 mg/g 
 group the was a 33.3% (4 out of 12, P = 0.0804) 
clearance of S. aureus carriage at 24 hours after 2 doses (total dose 0.6 mg of XF-73) and 
a 50% (6 out of 16, P = 0.0455) clearance of S. aureus carriage at 48 hours after 4 doses 
(total dose 1.2 mg of XF-73) over placebo. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
28 
Table 6.1: 
Analysis of Direct Plating Score Response Rate (ITT Population) 
– Study XF73-B03 
Time Point 
XF-73 2.0 mg/g 
 
(2d) 
N=24 
XF-73 0.5 mg/g
 
(2d) 
N=12 
Placebo (2d) 
N=24  
Day 2 
102  
(a total of 2.4 mg XF-73) 
41.7%  
7.86 (1.32, 80.65)  
0.0087  
42 
(a total of 0.6 mg XF-73) 
33.3%  
5.50 (0.61, 68.03)  
0.0804  
21 
 
8.3%  
EOT+12h 
92  
(a total of 4.8 mg XF-73) 
37.5%  
3.0 (0.66, 15.63)  
0.0965  
62  
(a total of 1.2 mg XF-73) 
50.0%  
5.0 (0.82, 31.8)  
0.0455  
41  
 
16.7%  
CI=confidence interval; EOT=end of treatment; HPC=hydroxypropyl cellulose 
1 Number of Responders, Response Rate  
2 Number of Responders, (total dose), Response Rate; Comparisons v Placebo - Odds Ratio (Exact 95% 
CI), One-sided Fisher Exact Test p-value using 2.5% significance level. 
 
In addition, the analysis of semi-quantitative S. aureus scores during the treatment period 
also showed a more marked decrease from baseline in the 2 XF-73 treatment groups than 
in the placebo group. This same difference was shown in the analysis of mean differences 
in AUC during the treatment period and it was statistically significant with better 
responses for the XF-73 groups. Moreover, statistical AUC analysis and the change from 
baseline in the reduction in S. aureus semi-quantitative scores there was an apparent dose 
response relationship with the higher 2.0 mg/g XF-73 dosage performing better than the 
0.5 mg/g dosage. 
In conclusion, these data from the study suggest that the highest concentration of XF-73 
(i.e., 2.0 mg/g) should be used to get a maximum response and that an efficient dose 
should be provided right before the point of highest risk for development of post-
operative infections (i.e., right before surgery). 
In the healthy volunteer study DMID11-007, 52 healthy volunteers (safety population) 
who were nasal persistent carriers of S. aureus received XF-73 nasal gel (0.5 mg/gr) 
 
 or XF-73 nasal gel (2.0 mg/gr) 
 or XF-73 nasal gel (0.5 mg/gr) 
 or 
placebo in each naris every 8 hours on Day 1 and every 12 hours Days 2 to 5; this 
provided cumulative doses of XF-73 of 3.3 mg, 13.2 mg and 3.3 mg respectively. 
Thirteen volunteers were randomly assigned to each group. Burden of S. aureus in the 
naris was measured as semiquantitative S. aureus scores during the 5-day treatment 
period and up to discharge (up to Day 6).  
The efficacy data for the treatment period supported the conclusions from study 
XF73-B03. Early in treatment there were important differences in the number of 
volunteers achieving eradication of S. aureus from their nose between placebo and XF-73 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
30 
• There is no approved drug for S. aureus nasal decolonization to prevent post-
operative staphylococcal infections, the indication under study 
• Studies of nasal decolonisation of S. aureus show a significant variability in the 
microbiological measurements and an important placebo effect (up to 50%-60%) 
which supports the need for a placebo to appropriately assess the effect of XF-73.  
• S. aureus nasal decolonisation prior to surgery is not universally accepted practice 
and when practiced it is not done in a standard way, but with considerable 
variation in the products and dosing regimens used of each product; as these 
products are not approved for the intended indication.  
• The study’s primary endpoint is based on microbiological data, not clinical. No 
impact is expected on post-operative staphylococcal infections from the use of 
placebo as their incidence is low and the sample size not enough to detect it.  
• The IDMC will assess the incidence of post-operative staphylococcal infections. 
• Patients will receive skin decontamination prior to surgery and peri-prophylactic 
systemic antibiotics according to SOC at their centre. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
31 
7 
STUDY POPULATION 
Patients undergoing surgical procedures who are at risk of post-operative S. aureus 
infection due to patient carriage status are eligible to participate in the study. Only 
patients who test positive to S. aureus (MSSA or MRSA) by standardized rapid 
diagnostic test will be enrolled in the study. 
7.1 
Inclusion Criteria 
Individuals who meet all of the following criteria are eligible to participate in the study. 
1. 
Male or female patients between 18 and 75 years of age. 
2. 
Patients who are confirmed nasal S. aureus carriers by polymerase chain 
reaction (PCR) screen assay, and due to undergo surgical procedure. 
3. 
Patients who are willing to provide written informed consent. 
4. 
Patients who are willing and able (as per Investigator judgment) to complete all 
protocol specified visits and assessments. 
5. 
Woman of childbearing potential* with a negative urine pregnancy test 
(sensitive to 25 IU human chorionic gonadotropin [hCG]).  
* Women of childbearing potential are defined as those women between 
menarche and menopause who have not undergone permanent sterilisation. 
Permanent sterilisation methods include hysterectomy, bilateral salpingectomy, 
and bilateral oophorectomy 
 
7.2 
Exclusion Criteria 
Individuals who meet any of the following criteria are not eligible to participate in the 
study. 
1. 
Pregnancy (current) or currently lactating. 
2. 
Uncontrolled acute or chronic illness (as determined by the investigator) in 
addition to those requiring the planned surgical intervention. 
3. 
History of atopy, allergic reactions or hypersensitivity to the study medication 
or its components. 
4. 
Current upper respiratory tract infection, cold or influenza with significant 
nasal symptoms that might impact on the patient’s ability to comply with the 
gel application procedure. 
5. 
History of photosensitivity. 
6. 
Family history of porphyria. 
7. 
Use of intra-nasal topical or systemic antibiotics or anti-infectives within the 
last 4 weeks before screening. (Patients who screen positive for nasal carriage 
of S. aureus and receive topical or systemic antibiotics or anti-infectives which 
are not part of their prophylactic peri-operative SOC between screening and 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
32 
first dose of IMP will be excluded from the study.) The use of intra-nasal 
antibiotics or anti-infectives other than the study medication prior to surgery is 
not allowed. 
8. 
Use of other prescribed or over the counter nasal medication in the last 14 days, 
or oral decongestants in the last 7 days before first administration of study drug. 
9. 
Participation in a clinical trial within the last 12 weeks before first 
administration of study drug. 
10. 
Contemporaneous clinically significant abnormalities in vital signs or 
laboratory analyses reported within 14 days prior to randomization which in the 
opinion of the Investigator would preclude from the safety assessment of the 
medication under study. 
11. 
Nasal polyps or significant anatomical or other nasal abnormality that would 
prevent from appropriate administration of the study treatment or represent an 
excessive risk for the patient’s participation. 
12. 
History of nasal surgery including cauterization. 
13. 
A recent history of frequent epistaxis and/or an episode of epistaxis within 3 
months of the planned surgery. 
14. 
Use of in situ nasal jewellery or existence of open nasal piercings. 
7.3 
Patient Withdrawal 
7.3.1 Reasons for Withdrawal 
Participation is strictly voluntary. Patients must be withdrawn from the study for any of 
the following reasons: 
• 
Withdrawal of informed consent; 
• 
Pregnancy; 
• 
Investigator’s opinion that it is in the best interests of the patient; 
• 
Patient is not willing or able to comply with study requirements 
If a patient withdraws from a trial prematurely, the Investigator must determine the 
primary reason for this and record it in the electronic case report form (eCRF). For 
patients who are lost to follow up, the Investigator should show due diligence by 
documenting in the source documents steps taken to contact the patient. 
7.3.2 Replacement of Patients 
Patients who withdraw or who are prematurely withdrawn from the study having received 
study medication will not be replaced but will be followed-up for safety as far as practical 
for inclusion into the safety dataset. 
7.4 
Patient Identification and Randomization 
At screening, each patient will be given a unique 5-digit number to facilitate anonymous 
identification within the study. The first 2 digits of the number is the centre number (i.e., 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
33 
01, 02, etc.). The following 3 digits will be enrolment order number (i.e., first patient at 
centre number 01 is number 01-001 then 01-002, etc). Once assigned to a patient, a 
patient number will not be re-used. This number will be used throughout the study as the 
subject identifier. 
A randomisation schedule will be prepared by an independent statistician and provided to 
Interactive Response Technology System (IRT) personnel prior to commencement of the 
study. This list will be maintained in the IRT system, under restricted access, until after 
study unblinding occurs. Patients will be randomly allocated in a 1:1 ratio as follows: 
0.2% w/w XF-73 nasal gel treatment OR placebo to match XF-73 nasal gel treatment. 
At randomisation, the IRT will assign an investigational product (IP) pack number. The 
pharmacist or qualified designee will retrieve the appropriate cardboard carton with the 
corresponding number. If a second bottle is needed, e.g. because syringe time to use has 
exceeded 48 hours from preparation, the pharmacist or qualified designee will use the 
IRT system to ascertain the second IP pack number required for the subject. Detailed 
instructions will be provided in the Pharmacy and IRT Manuals. 
7.5 
Stopping and Discontinuation 
An IDMC will be set up which will review the safety information from the study as well 
as the incidence of post-operative staphylococcal infections. Should these reach an 
unexpectedly high level, the IDMC can recommend stopping the study, the decision will 
be communicated to the sponsor as well as investigator sites, competent authorities, and 
ethics committees/IRBs. The IDMC charter containing, amongst other things, 
membership, meetings frequency, stopping criteria, structure and procedures  produced 
before randomization of the first patient will be updated implementing the changes 
introduced in this version 2.1 of the protocol.  

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
36 
and an additional 0.3mL dose applied to the contralateral naris. The total volume of study 
drug dispensed on each dose occasion will be 0.6 mL (2 × 0.3 mL equating to 1.2 mg of 
XF-73). Each bottle contains sufficient gel to withdraw 10 × 0.3 mL volumes 
(5 administrations to each nares). The nasal gels are preserved, but care must be taken 
during the opening of the bottle, withdrawal of doses and closing of the bottle to ensure 
the integrity of the product is maintained and not contaminated. If necessary, the syringes 
can be prepared up to 48 hours in advance of dosing. It is expected that doses 1, 2, 3, and 
4 will be prepared at the same time. 
Detailed instructions for the preparation and handling of the syringes from the supplied 
study drug will be provided in the Pharmacy Manual. Detailed instructions for the 
application of the nasal gel to the anterior nares will be provided in the Administration 
Manual. 
8.4 
Packaging, Labelling and Storage 
0.2% w/w XF-73 Nasal Gel and placebo to Match XF-73 Nasal Gel will be provided in 
bottles with screw top caps. Each bottle contains 
s of gel, sufficient to 
allow removal of at least 10 × 0.3 mL of gel as per protocol. The label on each bottle/kit 
does not identify the treatment arm (active or placebo) the nasal gel is assigned to. The 
bottles will be packaged in individual cardboard cartons as part of a patient kit. Each kit 
contains 1 bottle of nasal gel (active or placebo) 1 mL luer slip tip syringes, syringes 
caps, sterile wipes, syringe labels and a zip-lock foil bag in which filled syringes can be 
stored until use. Each bottle/kit will include a pack number which will be allocated to a 
single patient using the IRT system. Study drug will be labelled in accordance with 
applicable regulatory requirements. 
The study drugs must be stored at room temperature, below 25˚C and protected from 
light (by storing in the cardboard carton). The study drug must not be refrigerated or 
frozen. Each bottle and kit containing study drug is labelled with an expiry date. The 
shelf life of the study drug is under constant review based on data availability from 
ongoing stability studies on the batches used in the study and previous batches produced, 
and it is expected to be at least 12 months for each product. Until dispensed, the study 
drug must be stored in a securely locked area, accessible to authorized pharmacy or 
qualified designee personnel only. 
Syringes prepared for the administration of the study drug can be prepared up to 48 hours 
in advance of dosing, in accordance with instruction in the Pharmacy Manual and should 
be stored in the foil zip-lock bag provided until use. It is expected that doses 1, 2, 3, and 4 
will be prepared at the same time. 
Packaging and labelling of study drug will comply with Good Manufacturing Practice 
(GMP), Good Clinical Practice (GCP) rules, and country specific regulatory 
requirements; this information will be available in the local language. 
8.5 
Drug Accountability 
The pharmacist or qualified designee must keep a record of the dates and amounts of 
study drug received, dispensed and left unused at the end of the study. He or she will also 
have responsibility for ensuring the correct pack number is assigned to each patient based 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
37 
on the IRT assignment. The pharmacist or qualified designee is responsible for 
maintaining accurate study drug accountability records throughout the study. 
Each dispensing of study drug will be documented in the Pharmacy File and the time of 
administration should be captured in the eCRF. Any unused prepared syringes will be 
kept in their zip-lock foil bag at pharmacy for accountability and reconciliation. 
The study drug records must be available for inspection by the Sponsor’s representative 
and is subject to inspection by a regulatory agency at any time. Copies of the records will 
be provided to the Sponsor at the end of the study. A Clinical Research Associate (CRA) 
will review the study drug records. Any remaining study drug will be either returned to 
the Sponsor or destroyed at site in accordance with the site’s Standard Operating 
Procedures following final accountability by the CRA. 
8.6 
Compliance 
Patients will be considered compliant if they receive the 5 scheduled applications (4 prior 
to surgery and 1 after surgery) of randomized study drug. 
8.7 
Concomitant Medications 
Any medication the patient takes other than the study drug is considered a concomitant 
medication. All concomitant medications must be recorded in the eCRF. The following 
information must be recorded in the eCRF for each concomitant medication: generic 
name, route of administration, start date, stop date, dosage, and indication. Any changes 
in the dosage or regimen of a concomitant medication must be recorded in the eCRF. 
At randomization, patients will be asked what medications they have taken during the last 
30 days. Changes to concomitant medications will be captured throughout the study and 
follow-up periods. 
The use of intra-nasal antibiotics or anti-infectives other than the study mediation prior to 
surgery is not allowed. 
8.8 
Treatment of Overdose 
There have been no reports of XF-73 overdose or off-target application and under the 
conditions of the study protocols, the possibility has been minimised, as site staff 
administer the product. Please see the Pharmacy and Administration Manual for 
additional information about overdose or off-target application. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
38 
9 
PARAMETERS AND METHODS OF ASSESSMENT 
9.1 
Microbiological Assessments 
9.1.1 Screening 
Potentially suitable patients who provide written informed consent to nasal swabbing and 
microbiological analysis will be assessed for nasal S. aureus carriage. 
Specimens for detection of S. aureus will be collected using commercial nasal swabs. 
Each specimen will be collected from the anterior naris, and the swab will be immersed 
in the accompanying transport medium container for transfer to the microbiological 
laboratory. PCR will be used for the rapid detection and identification of S. aureus at 
screening. The swab will be processed by a standardized laboratory process using an 
FDA-cleared commercial rapid diagnostic test, the 
 
 to confirm S. aureus and identify whether it is MSSA or 
MRSA. This test will confirm presence or absence of MSSA or MRSA in nasal swab and 
will be used for inclusion in the study.  
Only subjects who are S. aureus positive by the rapid diagnostic test (and meeting other 
criteria) will be enrolled to the study.  
9.1.2 Treatment and Follow-up Periods  
Patients who test positive for S. aureus at screening and provide consent for the main 
study will have nasal swabs taken at the following times 
1. Prior to Dose 1 (22 hours (± 2 hours) prior to surgery; quantitative). 
2. Prior to Dose 3 (6 hours (± 2 hours) prior to surgery; quantitative) 
3. Prior to Dose 4 (Up to 1 hour prior to incision; quantitative) 
4. Prior to Dose 5 (Up to 1 hour post wound closure; quantitative) 
5. 48 hours (± 24 hours) after surgery (quantitative) 
6. 6 days (± 24 hours) after surgery (quantitative) 
 
Swabs will be transferred to the microbiological laboratory and standard microbiology 
culture techniques will be used to quantify the number of bacteria in CFU/mL at each 
timepoint.  
In order to appropriately assess the incidence of post-operative staphylococcal infections 
investigators will take all reasonable efforts to obtain microbiological documentation and 
a bacterial isolate when the suspicion of post-operative infection is raised. This includes 
but is not limited to the collection and culture of exudates, blood, implant or other 
specimens according to the suspected site of infection. Isolates of Staphylococcus spp. 
obtained from these cultures will be kept for further analysis and characterization (e.g., 
genotypic and phenotypic characterization). 
These samples as well as those bacterial isolates obtained from the nasal swabs during the 
study will kept for up to 10 years after the completion of the study for further phenotypic 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
39 
and genotypic analysis and characterization. The details of these tests are not known at 
this time. No subject identifying information will be retained for these samples. The 
Informed Consent Form explains the storage and future use of specimens and subjects 
will be asked to consent for future testing of samples. 
The Sponsor and Sponsor contracted vendors will have access to the samples and will 
perform microbiological work on behalf of the sponsor. Additionally, bacterial isolates 
may be shared with academic researchers. 
As these are bacterial samples, no human genetic testing will be performed. 
9.1.3 Microbiological Specimen Collection and Culture for S. aureus 
The Laboratory Manual of Microbial Procedures will describe the details of collection 
and processing methods for microbiological samples, including type of nasal swab and 
transport tube, microbiological culture methods, and reporting of results. 
9.2 
Efficacy Parameters 
Efficacy will be assessed by measuring CFUs/mL at the time points outlined in the 
Schedule of Assessments (Table 1.1) the incidence of post-operative staphylococcal 
infections as well as use of post-operative anti-staphylococcal antibiotics. 
Any staphylococcal post-operative infections arising between study treatment and up to 
30 or 90 days (if foreign implant) included but not limited to SSI, bloodstream infections, 
catheter-related infections, and implant infections are to be captured as events indicating 
lack of efficacy. These should NOT be captured as safety TEAEs. 
9.3 
Safety Parameters 
Safety will be assessed by incidence of AEs, clinical laboratory parameters, vital signs, 
physical examinations, nasal examination, and the B-SIT. 
9.3.1 Adverse Events 
All AEs, whether identified by the Investigator or the study patient from screening to 
Day 6, will be recorded in the eCRF. Measurement of vital signs and clinical laboratory 
parameters will be performed pre- and post-study and clinically significant values will be 
captured as AEs. For AEs occurring after Day 6, see section 9.3.1.2 of this protocol. 
9.3.1.1 Definitions 
Per ICH, an AE is defined as any untoward medical occurrence in a patient or clinical 
investigation patient administered a pharmaceutical product and which does not 
necessarily have a causal relationship with this treatment. An AE can therefore be any 
unfavourable or unintended sign (including an abnormal laboratory finding), symptom, or 
disease temporally associated with the use of a medicinal (investigational) product, 
whether or not related to the medicinal (investigational) product. The AE may be any of 
the following: 
• A new illness 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
40 
• An exacerbation of a sign or symptom or the underlying condition or of a 
concomitant illness under treatment 
• Unrelated to participation in the clinical study or an effect of the study medication 
or comparator drug 
• A combination of 1 or more of the above factors 
No causal relationship with the study medication is implied by the use of the term AE. 
Planned or elective surgical or invasive procedures for pre-existing conditions that have 
not worsened are not AEs. However, any complication that occurs during a planned or 
elective surgery is an AE. Conditions leading to unplanned surgical procedures may be 
AEs.  
When an AE occurs after written consent has been obtained but before the first dose of 
study drug, the AE will be considered a non-treatment emergent AE. An AE that occurs 
from the time the patient receives his/her first dose of study drug until his/her last study 
visit will be considered a TEAE regardless of the assessed relationship to the 
administration of the study drug. 
Serious Adverse Event (SAE) 
An SAE is any untoward medical occurrence that: 
• Results in death 
• Is life-threatening (Note: the term “life-threatening” refers to any AE that, as it 
occurs, puts the patient at immediate risk of death. It does not refer to an AE that 
hypothetically might have caused death if it were more severe). 
• Requires hospitalization or prolongation of existing hospitalization (not including 
hospitalization for a pre-existing condition that has not increased in severity or 
frequency from the patient’s underlying medical condition prior to entry into the 
study). Hospitalization for an elective procedure, or routinely scheduled treatment for 
a pre-existing condition that has not worsened, is not an SAE. 
• Results in persistent or significant disability or incapacity 
• Is a congenital anomaly or birth defect 
• Is another medically important condition  
 
An important medical event that is not immediately life threatening or will result in death 
or hospitalization, but which may jeopardize the patient or may require medical 
intervention to prevent one of the outcomes listed above, should be reported as “serious” 
as well. 
Medical and scientific judgment should be exercised in deciding whether a case is 
serious. 
“Occurring at any dose” does not imply that the patient is receiving study drug at the time 
of the event.  

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
41 
Severity of Adverse Event:  
Refers to the extent to which an AE affects the patient's daily activities. Severity will be 
categorized according to the following criteria: 
Mild: 
The AE does not interfere with the patient’s routine activities. 
Moderate: 
The AE interferes with the patient’s daily routine, but usual routine 
activities can still be carried out. 
Severe: 
The AE results in the inability to perform routine activities. 
The term "severity" is used to describe the intensity of an event. This is not the same as 
"serious". Seriousness, not severity, serves as the guide for defining regulatory reporting 
obligations. The highest severity grade attained should be reported, for AEs with 
divergent severities. 
Causality of Adverse Event:  
Refers to the relationship of the AE to study drug. Causality will be reported according to 
the following criteria: 
Not 
related: 
Adverse events for which a reasonable explanation for an alternative cause 
is considered plausible, e.g., no study drug taken, plausible clinical 
alternative like accidental injury, expected progression of underlying or 
concomitant disease, pharmacologically incompatible temporal relationship, 
or intercurrent illness. 
Related: 
Adverse events for which a reasonably possible clinical and/or 
pharmacological relationship to study drug cannot be excluded, e.g., lacking 
plausible alternatives. 
 
9.3.1.2 Recording Adverse Events 
Patient Enrolment to the First Administration of Study Drug: Non-treatment 
emergent AEs will be recorded from the time when the patient is enrolled into the study 
(date of signature of the screening informed consent) until first administration of study 
drug. These events will be recorded in the medical history section of the eCRF. 
First Administration of Study Drug to Patient's Day 6 visit: Thereafter, all AEs are 
TEAEs and will be recorded until Day 6 visit has been performed.  
After Day 6: Only AEs that meet SAE criteria and are considered related with the study 
medication by the investigator will be recorded after Day 6 through the final follow up 
visit. 
If an AE (serious or not) started during the study but did not end before the final 
follow-up visit, the Investigator should make a reasonable effort to establish the outcome 
and the end date. If this is not possible, the outcome recorded at the final follow-up visit 
will be assumed to be the final outcome. 
If an event stops and later restarts, all the occurrences must be reported. If in a patient the 
same event changes in intensity over time (e.g., diarrhoea starting as mild turns into 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
42 
severe), only the most severe intensity will be recorded. All AEs assessed as related to 
study medication by the Investigator and all SAEs must be followed up until resolution. 
(e.g., value back to baseline value) or stabilization or until final database lock. 
Signs/symptoms should be documented if a definite diagnosis cannot be established. The 
Investigator should attempt to establish a diagnosis of the event based on signs, 
symptoms and/or other clinical information. In such cases, the diagnosis should be 
documented as the AE and/or SAE and not the individual signs/symptoms. If a diagnosis 
is accompanied by unusual symptoms, both the diagnosis itself and the symptoms will be 
reported. 
After Patient's Last Study Visit: The Investigator records and forwards to the Sponsor 
all SAEs that she or he becomes aware of and she or he considers related to the study 
drug. 
Laboratory values that are outside the normal range and considered clinically 
relevant in the opinion of the Investigator are also defined as AEs. 
If abnormal laboratory values are signs of an AE (e.g., an infection) that has already been 
recorded, the respective abnormal laboratory value does not constitute a separate AE. 
Wherever reasonable the reporting Investigator will use the clinical term rather than the 
laboratory term (e.g., anaemia versus low haemoglobin value). 
9.3.1.3 Responsibilities of the Investigator 
The AE data should be obtained through observation of the patient, from any information 
volunteered by the patient, or through patient questioning. The general type of question 
asked could be similar to: “Do you have any health problems?” or “Have you had any 
health problems since your last clinic visit?” 
All AEs are to be documented/recorded accurately and completely on the AE pages of the 
respective eCRF and in the patient's source data.  
All non-treatment and TEAEs will be recorded through Day 6. 
This is true even if the study drug was not administered according to the study protocol. 
For conditions leading to unplanned surgical procedures the underlying condition, should 
be documented as an AE, but not the procedure. For withdrawals due to AEs these 
should be captured in the CRF. If the AE meets the criteria of an SAE, it should be 
reported to 
 as normal. 
Overdose needs to be captured as an AE in the CRF and reported to 
 
if the AE meets the criteria of an SAE. 
9.3.1.4 Responsibilities of the Sponsor 
For purposes of safety analyses all AEs will be recorded in the clinical database. To 
ensure expedited and periodic notification of authorities, SAEs will also be recorded in 
the drug safety database. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
44 
Patients that have unresolved AEs, clinically relevant laboratory parameters or SAEs 
after Day 6 (including the Early Termination Visit), should be followed by the 
Investigator until satisfactory resolution (e.g., value back to baseline value) or 
stabilization or until final database lock. If necessary, in order to obtain the additional 
information, the Investigator may request additional physical examinations to be 
completed or additional blood or urine samples to be taken. The assessments measured 
will be determined by the Investigator. All data must be documented in the eCRF. 
Destiny Pharma’s regulatory advisors 
 are 
responsible for fulfilling all sponsor obligations regarding notification of the FDA 
according to applicable regulatory requirements (expedited and periodic reporting, e.g., 
SUSARs, Development Safety Update Report). In addition, 
 will provide 
safety information arising from the authorities of countries other than the US and to 
Investigators according to the current regulations and ensure that the Investigators notify 
their IEC/IRB. 
9.3.2 Pregnancy 
If a female patient or the female partner of a male patient becomes pregnant during the 
study or 30 days after study completion, the patient should notify the Investigator 
immediately, who will report the event to 
. The pregnancy will be 
followed until termination or birth of the baby.  
9.3.3 Laboratory Parameters 
Laboratory references from certified central laboratories will be used. All results of 
laboratory tests will be entered in the study database.  
The tests listed in Table 9.1 will be conducted on samples collected and analysed by 
standard laboratory procedures at the time points designated on the Schedule of 
Assessments (Table 1.1). Tests that are not done must be reported as such on the eCRFs. 
Table 9.1: 
Laboratory Parameters 
Haematology 
 
 
Complete blood count 
including Red blood cell 
(RBC) count 
Haemoglobin 
RBC indices and red cell 
diameter width (RDW) 
Haematocrit, 
White blood cell (WBC) total and 
differential count 
Platelet count 
Clinical Chemistry 
Serum sodium 
(bicarbonate) 
Creatinine 
Alanine aminotransferase 
(ALT) 
Aspartate aminotransferase 
(AST) 
Alkaline phosphatase 
 
Potassium 
Chloride 
Glucose (screening), Glucose; 
Record the time the patient last 
ate for all glucose levels 
Total protein, and Albumin 
Total bilirubin 
 
Carbon dioxide (CO2) 
Blood urea nitrogen (BUN) 
Calcium 
Magnesium 
Phosphate 
Uric Acid 
Urine 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
45 
Table 9.1: 
Laboratory Parameters 
Dipstick with reflex urine microscopic examination may be done at the investigator’s discretion if the 
dipstick test is positive for blood, nitrites, protein, and/or leukocyte esterase.  
Pregnancy Testing (female 
patients only) 
Urine human chorionic gonadotropin (hCG)  
 
All laboratory reports will be reviewed and any values outside the normal range will be 
commented on by the Investigator or qualified designee. The reports will then be signed 
and dated. The laboratory reports will remain with the source documents and the 
Investigator’s comments will be recorded in the eCRF along with the date and time of the 
sample collection.  
9.3.4 Vital Signs 
Vital signs will be measured and recorded at the time points designated on the Schedule 
of Assessments (Table 1.1). All measurements will be recorded on the vital signs eCRF. 
Abnormal test results may be repeated at the discretion of the Investigator and must be 
reported on the corresponding eCRF. When vital signs and/or blood sample collection 
occur at the same time, vital signs should be performed before blood sample collection. 
9.3.5 Physical Examinations 
The Investigator or qualified designee will perform a complete physical examination 
(including nose and nasal passages) at the Randomisation Visit (Table 1.1). Pre-dose 
abnormal findings will be reported on the medical history eCRF. After that, brief, 
symptom-driven physical examinations (including nose and nasal passages) will be done. 
Any adverse change from the baseline physical examination at Randomisation Visit will 
be documented on the AE eCRF (except those occurring prior to first study medication 
application which will be reported in the medical history eCRF).  
A complete physical examination will include inspection of general appearance, skin, 
neck (including thyroid), eyes, ears, nose and nasal passages, throat, heart, lungs, 
abdomen, lymph nodes, extremities, musculoskeletal system, and nervous system.  
9.3.6 Assessment of Nose, Nasal Passages, and Sense of Smell  
9.3.6.1 Nasal Examination by ENT specialist 
Nose and nasal passage examinations will be conducted by an ear nose and throat  (ENT) 
specialist at the time points designated on the Schedule of Assessments (Table 1.1). 
The standard nasal examination will consist of evaluation of both nares and the nasal 
passages for mucosal erythema, oedema, and secretions. Note that the test article is a red, 
viscous gel, and as such, this should be considered during assessments. 
9.3.6.2 Brief Smell Identification Test™ 
In the study, patients are required to complete the B-SIT, also known as the University of 
Pennsylvania B-SIT at the time points designated on the Schedule of Assessments 
(Table 1.1). 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
46 
The B-SIT is self-administered and consists of 1 enveloped-sized booklet containing 
12 “scratch and sniff” odorants. Each odorant strip has a multiple-choice question with 
4 alternative responses. The patient is required to mark one of the 4 alternatives even if 
no smell is perceived. These scores will be recorded in the eCRF. 
A percentile score is established which measures an individual’s olfactory diagnosis. 
Both patients scores will be reviewed by an Investigator. If the patient’s olfactory 
diagnosis at Follow-Up (Day 6) has significantly worsened, this will be recorded as an 
AE and relationship determined.  
 
 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
47 
10 STUDY CONDUCT 
10.1 Observations by Visit 
10.1.1 Screening Visit (Day -14 to Day -1) 
Patients will be asked to sign a screening informed consent form (ICF) prior to 
undergoing nasal swabbing for rapid S. aureus testing. Patients will be given a full 
explanation of the nature of the study and the main study ICF will be provided. As the 
results from the standardized 
 rapid test will take a 
few hours, the patient will have time to become familiar with the main study ICF and 
compose questions if the swab result is positive for S. aureus.  
10.1.2 Randomization Visit (Day -10 to Day -1) 
If the patient is tested S. aureus positive, the following procedures are to be completed 
(Table 1.1): 
• Obtain consent for the main study. Patient’s informed consent to the study will be 
documented before any Randomization Visit study-specific assessments or 
procedures are performed. 
• Verify eligibility (inclusion/exclusion criteria) 
• Record demographic data including sex, age, race, and ethnicity 
• Record medical/surgical history (including any risk factors for S. aureus carriage) 
(Risk factors include: HIV infection, obesity, diabetes, granulomatosis with 
polyangiitis, rheumatoid arthritis, skin and soft tissue infections, recurrent 
furunculosis, atopic dermatitis, smoking, hormonal contraception use, hospital 
workers, haemoglobin in nasal secretions, histocompatibility antigen phenotype 
HLA-DR3, and polymorphisms in genes encoding for the glucocorticoid receptor, 
interleukin-4, C-reactive proteins and complement inhibitor proteins.) Any 
potential AEs related to the screening swab (in the investigator’s judgment) 
should be recorded as medical history.  
• Record previous (4 weeks prior) and current medications 
• Perform a complete physical examination  
• Examination of the nose and nasal passages by an ENT specialist 
• Measure and record vital signs (heart rate and supine blood pressure [BP]) 
• Draw blood for haematology and clinical chemistry  
• Collect urine sample for urinalysis and pregnancy test 
• Record SOC in skin decontamination and peri-operative prophylactic regimen 
• Record AEs 
• -B-SIT 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
48 
• Randomization to study drug after eligibility is verified (may occur from Day - 7 
to Day -1 prior to dose 1) 
10.1.3 Treatment Period (Days -1 to Day 0) 
Patients who meet the entry criteria will undergo the following treatment visits and 
assessments at timepoints designated on the Schedule of Assessments (Table 1.1). All 
assessments should be completed prior to the dose of study drug. Treatment visits will 
normally occur in hospital, however if more convenient for the patient, home visits by 
qualified staff working to an agreed process will be allowed. 
 
It is normally expected that patients will continue as planned to their pre-determined 
surgery time and date after the initial pre-surgical doses of IMP in the previous 24 hours. 
However, in clinical practice surgery can be postponed at any point in the lead up to the 
planned surgery time and date for different reasons and would not be considered a 
protocol deviation. If surgery is delayed, then the following steps should be followed. 
• If the delay to the planned incision timepoint is less than or equal to 48 hours, the 
patient should continue with the remaining doses as per protocol to the new 
timeframe. The remaining IMP must be checked to be within its own 48hr expiry 
window or replaced with a new kit assigned by the IRT system.  
• If the delay to the planned incision timepoint is greater than 48 hours but the 
patient’s new surgery date and time is still within their screening window, then 
existing IMP should be replaced and a new kit assigned to the patient and full 
dosing regimen provided according to the protocol to the new timeframe. 
• If the delay to the planned incision timepoint is greater than 48 hours and the 
patient’s new surgery date and time is outside their screening window, then the 
patient should be withdrawn. If time permits, the patient can be re-screened using 
a new screening number. 
10.1.3.1 First dose visit (Day -1) 
• Verify eligibility (inclusion/exclusion criteria) 
• Randomization to study drug if not completed prior to Day -1 
• Record changes in medical history and concomitant medications from 
randomization visit. 
• Perform a brief symptom-driven physical examination or a complete medical 
examination if it was not performed at randomization visit. 
• Examination of the nose and nasal passages by the ENT specialist (only if not 
performed during randomization visit) before drug application. 
• Nasal swabbing for quantification of S. aureus within 1 hour prior to drug 
application 
• Record SOC in skin decontamination and peri-operative prophylactic regimen 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
49 
• B-SIT before drug application if not performed during randomization visit. 
• Record AEs 
• Record concomitant medications. 
• First application of assigned study drug at 22h ±2h before surgery (estimated 
incision time) 
10.1.3.2 Second dose visit (Day -1) 
• Record SOC in skin decontamination and peri-operative prophylactic regimen 
• Second application of assigned study drug at 14h±2h before surgery (estimated 
incision time) 
• Record AEs  
• Record concomitant medications. 
10.1.3.3 Third dose visit (Day 0) 
• Nasal swabbing for quantification S. aureus within 1 hour prior to drug 
application 
• Record SOC in skin decontamination and peri-operative prophylactic regimen 
• Third application of assigned study drug at 6h±2h before surgery (estimated 
incision time) 
• Record AEs  
• Record concomitant medications. 
10.1.3.4 Fourth dose visit (Day 0)  
• Nasal swabbing for quantification of S. aureus within 1 hour prior to drug 
application 
• Record SOC in skin decontamination and peri-operative prophylactic regimen  
• Application of fourth dose of study medication within one hour before incision 
(e.g. in the operating room). 
• Record number of blood glucose records from time of admission to hospital for 
surgery and how many were over 200 mg/dL. 
• Record number of body temperature measurements from time of admission to 
hospital for surgery and how many were under 35.5o C. 
• Record AEs  
• Record concomitant medications 
10.1.3.5 Fifth dose visit (Day 0) 
• Measure and record vital signs (heart rate and supine BP) 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
50 
• Nasal swabbing for quantification of S. aureus within 1 hour prior to drug 
application 
• Record SOC in skin decontamination and peri-operative prophylactic regimen 
• Application of fifth dose of study medication within 1 hour after closure of 
incision (e.g. in the operating room) 
• Record number of blood glucose records from visit dose 1 and how many were 
over 200 mg/dL. 
• Record number of body temperature measurements from visit dose 1 and how 
many were under 35.5o C.  
• Draw blood for haematology and clinical chemistry after study medication 
application 
• Collect urine sample for urinalysis after study medication application. 
• Record AEs  
• Record concomitant medication 
10.1.4 Follow-up Period  
10.1.4.1 Post-surgical visit (48h ± 24h post closure of surgical incisions) 
• Complete brief symptom-driven physical examination 
• Examination of the nose and nasal passages by the ENT specialist 
• Nasal swabbing for S. aureus 
• Record SOC in skin decontamination and peri-operative prophylactic regimen 
• Measure and record vital signs (heart rate and supine BP) 
• Draw blood for haematology and clinical chemistry 
• Collect urine sample for urinalysis 
• Record concomitant medications 
• Record AEs  
• Record staphylococcal infections and use of antibiotics from visit dose 5. 
10.1.4.2  Follow Up (Day 6 (± 24 hours) 
• Complete brief symptom-driven physical examination (including nose and nasal 
passages) 
• Nasal swabbing for S. aureus 
• Measure and record vital signs (heart rate and supine BP) 
• Draw blood for haematology and clinical chemistry 
• Collect urine for pregnancy test 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
51 
• B-SIT 
• Record concomitant medications. 
• Record AEs 
• Record staphylococcal infections and use of antibiotics 
10.1.4.3 Follow-up (Day 30) 
• Record staphylococcal infections and use of antibiotics 
• Record suspected IP related SAEs, only 
• Record concomitant medications 
10.1.4.4 Follow-up Day 90 (Only if object implant in surgery) 
• Record staphylococcal infections and use of antibiotics 
• Record suspected IP related SAEs, only 
• Record concomitant medications 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
52 
11 STATISTICAL METHODS 
11.1 Disposition of Patients 
The numbers and percentages of patients enrolled, randomized, treated, discontinued with 
associated reasons and completed in the Safety, Intent-to-treat (ITT) and Per-protocol 
(PP) will be tabulated for each treatment group.  
The reasons for patient exclusions from each of the populations of interest will be listed. 
11.2 Protocol Deviations 
Major protocol deviations are compliance issues that have an impact on patient safety or 
the scientific integrity of the study data. All deviations will be evaluated and classified as 
major or minor before database lock and unblinding.  
11.3 Analysis Populations 
11.3.1 All Enrolled Patients  
All enrolled patients include all patients that completed main study informed consent 
(i.e., has a non-missing informed consent date).  
11.3.2 Safety Population 
The Safety Population will consist of all patients who received at least 1 dose of study 
drug. Patients will be presented in the actual treatment group that they received. The 
primary population for the safety analyses will be the Safety population. 
11.3.3 Intent-To-Treat Population 
The ITT Population will consist of all patients who were randomized. 
11.3.4 Modified Intent-To-Treat Population 
The modified ITT Population will consist of all patients who were randomized, received 
at least 1 dose of study drug and have at least 1 post-baseline assessment of S. aureus 
log10 CFU/mL. Patients will be presented in the treatment group that they were randomly 
assigned. 
11.3.5 Microbiological Intent-To-Treat Population 
The microbiological Intent-To-Treat (micro ITT) set will consist of all patients in the 
mITT set who have a log CFU/mL result at baseline greater than 0, i.e. all patients in the 
mITT set with a quantifiable baseline microbiological result. The primary population for 
the efficacy analyses will be the Micro ITT. 
 
 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
53 
11.3.6 Per-protocol Population 
The PP Population will consist of all patients in the micro ITT population without major 
protocol deviations. Supportive efficacy analyses will also be performed on the PP 
population for key endpoints and at key time points, as specified in Section 5. 
11.4 General Considerations 
A Statistical Analysis Plan (SAP) describing the planned final analysis up to Day 6 and 
separately for the 30-day and 90-day follow-up periods and including detail with tables, 
figures and listings templates will be developed as a separate document. 
• Continuous variables will be summarised using the number of patients with 
evaluable data, mean, standard deviation (SD), median, minimum and maximum. 
• Categorical variables will be summarised using the number of observations (n), 
frequency and percentage of patients. All percentages will be presented as one-
decimal point, unless otherwise specified. Percentages equal to 100 will be 
presented as 100% and percentages will not be presented for zero frequencies. 
11.5 Demographics, Baseline Characteristics and Concomitant Medications 
Demographic and baseline characteristic data will be summarised and listed by treatment 
groups by means of descriptive statistics. Further details will be provided in the SAP. 
Concomitant medications will be coded by using the World Health Organisation (WHO) 
Drug Dictionary and will be summarised by treatment group with the number and 
percentage of patients receiving concomitant medication by drug class and preferred drug 
name. A listing of all medications will be produced indicating whether the medication 
was taken prior to, during and/or after treatment. 
11.6 Treatment Compliance 
Treatment exposure will be summarised and listed by treatment group by means of 
descriptive statistics for categorical data (counts and percentages). The number of doses 
taken (range 1 to 5) will be reported for the Safety Population. 
11.7 Efficacy Analyses 
Primary analysis will be on the endpoint of change in log10 CFU from baseline to pre-
surgery using an analysis of covariance (ANCOVA) model including baseline CFU as a 
covariate. A similar analysis will also be performed for the endpoint of change from 
baseline to the post-surgery measurement.  
Secondary efficacy analyses will include; 
• Change in log10 CFU from baseline to post-surgery using an ANCOVA model 
including baseline CFU as a covariate. 
• A log10 AUC for CFUs will also be undertaken utilising data for all time 
points up until the pre-surgery assessment. This analysis of log10 AUC CFUs 
will also including baseline log10 CFU as a covariate. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
54 
• A log10 AUC for CFUs will also be undertaken utilising data for all time 
points up until the post-surgery assessment. This analysis of log10 AUC CFUs 
will also including baseline log10 CFU as a covariate. 
• Percentage of patients reaching a specific reduction in S. aureus carriage prior 
to surgery, immediately post-surgery and on Day 6 ± 24hrs 
• Proportion of patients with nasal carriage below a set value (value to be 
determined [TBD]) 
• Summary of data for nasal carriage according to SQS along with an analysis 
of proportional odds. 
• Summary of the proportion of patients with a 2-log drop (TBD)  
In addition to the planned analysis in the PP population which requires patients to receive 
4 doses of pre-surgery treatment, and additional sensitivity analysis will be performed 
which will include all patients who receive 3 doses of pre-surgery treatment. 
Analysis of post-operative infections and antibiotic use at Day30 and Day 90 will be 
performed separately to the main analysis period of randomisation Day 0 to follow-up at 
Day 6 and can be reported separately. 
11.8 Safety Analyses 
Safety will be determined by AEs, clinical laboratory parameters, physical examination, 
vital signs, microbiological specimen collection and nasal examination. 
All available data from patients in the Safety Population will be included in the 
assessment of safety and tolerability. All safety and tolerability data will be listed and 
summarised by treatment group using appropriate descriptive statistics. Formal statistical 
comparisons between the different treatment groups will not be conducted. 
All AEs will be coded using the MedDRA terminology. 
Further details will be provided in the SAP. 
11.9 Interim Analyses 
An interim analysis will be performed, depending on recruitment projections, when 
approximately 60% evaluable subjects have been recruited. The aims of this interim 
analysis are to: 
• Review the Safety data generated to date. 
• Review the incidence of post-operative staphylococcal infections. 
• Stop the study in case of serious concerns on subject’s safety 
• Stop the study due to the incidence of post-operative staphylococcal infections. 
The interim analyses will be performed by an independent statistician and will be 
performed using similar methodology to that for the main analysis. This approach will be 
described in further detail in the IDMC SAP.    
All study staff including the Sponsor will remain blinded until the end of the study.  

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
55 
Full details of these analyses and the role of the IDMC will be provided in the new 
version of the IDMC charter implementing the changes introduced in this version 2.1 of 
the protocol. 
11.10 Determination of Sample Size 
Individual CFU data is presented in the study of Verhoeven 201227 in the absence of 
treatment. As the primary population for the efficacy analysis is the micro-ITT, those 
values with zero CFU have been excluded and the resulting data have been converted to 
the log10 CFU scale. The SD of these values has been used as the estimate of variability 
for an analysis of change from baseline whilst including baseline log10 CFU as a 
covariate. As a result, a trial including 80 evaluable patients (40 per arm) would have a 
greater than 90% power to detect a true treatment effect of a 2 log10 CFU difference and 
an 90% power to detect a true treatment effect of a 1.5 log10 CFU difference between XF-
73 and placebo, assuming 2-sided alpha=0.05, a between patient SD of 2 log10 CFUs 
taken from the Verhoeven study.  
We estimate that approximately 125 patients will need to be recruited in order to have 
around 80 patients with a burden S. aureus nasal carriage which will allow for the 
detection of an effect of XF-73 nasal gel. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
56 
12 DATA MANAGEMENT 
12.1 Data Collection 
The trained Investigator site staff will enter the data required by the protocol into the 
eCRFs from source documents (e.g., medical records and study-specific data capture 
tools as needed) directly into the study database on a central server. All information in the 
eCRFs must be traceable to these source documents. Data recorded directly into the 
eCRFs will be defined before study start and the eCRFs will be considered the source 
data. Clinical Research Associates and a Data Manager will review eCRFs entered by 
investigational staff for completeness and accuracy. Automatic quality programs check 
for data discrepancies in the eCRFs and the resulting queries will be notified to the 
investigational site using an electronic data query process within the electronic data 
capture (EDC) system. Designated Investigator site staff are required to respond to 
queries and make any necessary changes to the data. Details of the data correction 
process will be specified in the Data Management Plan.  
A validated, electronic database will be employed from the EDC system. An audit trail of 
all changes to this database, including the date, reason for the data change and who made 
the change, will be maintained within the same database. The audit trail will be part of 
the archived data at the end of the study. 
The complete data management process (data capture, data entry, data validation, checks 
on plausibility, query handling, data editing after entry, coding, data base closure, etc.) 
will be defined in advance within a data handling plan/ data management plan together 
with a description of the personnel responsible for data entry. 
12.2 Data Correction 
Automatic and manual queries will be defined according to the data validation plan. 
These queries will be generated by the Destiny’s data management provider 
 
 and sent through the EDC system for clarification. Corrections will be entered 
directly into the system. This procedure will be repeated until all queries are resolved. All 
query forms will be linked to the eCRF in the EDC system. 
12.3 Data Handling 
The final data will be transferred to the SAS-system for data analyses in accordance with 
the SAP. The MedDRA dictionary will be used for coding of AEs and concomitant 
diseases. Concomitant medication will be coded using the WHO Drug Dictionary 
A(natomical) T (herapeutical C(hemical) code. 
12.3.1 Deviations from the Protocol 
Deviations from the protocol will be judged during the study and/or when an individual 
patient’s eCRF is completed (monitored).  
Before unblinding the data, a blinded data review meeting (BDRM) will take place where 
protocol deviations will be classified (major/minor protocol deviations) for statistical 
analysis. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
57 
12.4 Data Quality Assurance 
Destiny Pharma will conduct a site visit to verify the qualifications of each Investigator, 
inspect the site facilities, and inform the Investigator of responsibilities and the 
procedures for ensuring adequate and correct documentation. 
The Investigator is required to prepare and maintain adequate and accurate case histories 
designed to record all observations and other data pertinent to the study for each study 
participant. All information recorded on the eCRFs for this study must be consistent with 
the patients’ source documentation (i.e., medical records). 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
58 
13 QUALITY CONTROL AND QUALITY ASSURANCE 
13.1 Study Initiation Activities 
The Investigator(s) are informed about study objectives and methods, the inclusion and 
exclusion criteria, the time-schedule, and study procedures at a Pre-Study Visit by the 
monitor (if necessary), an Investigators’ meeting, and during the Site Initiation Visit by 
the monitor. 
13.2 Training of Site Staff 
The Investigator will ensure that everyone assisting with the clinical study is adequately 
informed about the protocol, the investigational product(s), and their study-related duties 
and functions. Furthermore, the Investigator will maintain a list of qualified persons to 
whom the Investigator has delegated study-related duties. 
13.3 Documentation and Filing 
13.3.1 eCRF System 
All data recorded according to this study protocol must be documented in an eCRF. The 
Investigator and persons authorized by the Investigator will be instructed about how to 
complete the eCRF. Entries in the eCRF must only be made by the Investigator or 
persons authorized by the Investigator. A list of all persons who are allowed to make 
entries in the eCRF must be available in each study site. 
The Investigator must verify that all data entries in the eCRF are accurate and correct. 
Entries will be checked against appropriate source documentation by the monitor. 
13.3.2 List of Patients (patient identification log) 
The Investigator will keep a confidential list of names of all patients participating in the 
study, so that the patients' records can be identified if necessary.  
In addition, the Investigator will keep a list of all patients screened on a screening log to 
document identification of patients who entered pre-study screening. If someone is not 
eligible to participate in the study, a reason must be provided. 
13.3.3 Source Data 
Per ICH, source data are defined as all information in original records and certified 
copies of original records of clinical findings, observations, or other activities in a clinical 
study necessary for the reconstruction and evaluation of the study. Source data are 
contained in source documents which comprise clinical documentation, data, and records 
(e.g., hospital records, clinical and office charts, laboratory notes, memoranda, patients' 
diaries or evaluation checklists, pharmacy dispensing records, recorded data from 
automated instruments, copies or transcriptions certified after verification as being 
accurate copies, microfiches, photographic negatives, microfilm or magnetic media, 
x-rays, patient files, and records kept at the pharmacy, at the laboratories and at 
medico-technical departments involved in the clinical study). 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
59 
13.3.4 Investigator Site File / Regulatory Binder 
Before site initiation 
 will provide an ISF/ Regulatory Binder to each site. 
The ISF will include essential documents as defined by the ICH GCP guideline and 
applicable local requirements. 
The Investigator will be responsible for the update and maintenance of the ISF, which 
will be reviewed periodically by the monitor(s). These documents will be reviewed 
during an audit by the Sponsor or an inspection by the Regulatory Authorities. 
All study-related documents are to be archived and stored according to legal 
requirements. 
Prior to destruction of study-related documents, the Investigator will contact the Sponsor 
for approval and conformation. 
13.4 Monitoring 
The CRA is responsible for checking the quality of data and ensuring that the 
investigative site is adhering to the study protocol. Additionally, the CRA ensures that the 
site is following the legal and ethical requirements as stated in local laws and the 
principles of GCP. 
The interval between monitoring visits will depend on the recruitment rate and the 
complexity of the study. 
Source data verification is an essential part of the monitoring process and the Investigator 
must grant direct access to the patient’s source data. 
The extent and nature of monitoring will be described in detail in the monitoring plan. 
13.5 Audits and Inspections 
Audits will be performed according to the corresponding audit program. The Sponsor’s 
Quality Assurance Department may visit the investigative site to audit the performance of 
the study, as well as all study documents. Audits may also be performed by contract 
auditors who will be instructed about the timing and extent of the audits. In the event of 
an audit at the investigational site, the monitor will usually accompany the auditor(s).  
Inspections by Regulatory Authority representatives and IECs/IRBs are possible at any 
time, even after the end of study. The Investigator is to notify the Sponsor immediately of 
any such inspection. The Investigator and institution will permit study-related 
monitoring, audits, reviews by the IEC/IRB and/or Regulatory Authorities and will allow 
direct access to source data and source documents for monitoring, audits, and inspections. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
60 
14 ETHICAL, LEGAL AND ADMINISTRATIVE ASPECTS 
14.1 Good Clinical Practice 
The procedures set out in this study protocol are designed to ensure that the Sponsor and 
Investigator abide by the principles of the GCP guidelines of the ICH, and of the current 
version of the Declaration of Helsinki (Brazil 2013). The study also will be carried out in 
keeping with local legal requirements.  
14.2 Informed Consent 
Before each patient is admitted to the study, a pre-screening nasal swab informed consent 
will be obtained from the patient (or his/her legally authorized representative) according 
to the regulatory and legal requirements of the participating country (i.e., the Declaration 
of Helsinki, ICH GCP, US Code of Federal Regulations for Protection of Human Patients 
(21 Code Federal Regulation [CFR] 50.25 (a) and (b), CFR 50.27, and CFR Part 56, 
Subpart A), and other applicable local regulations). If the patient is S. aureus positive, 
he/she will be asked to sign the main ICF. This consent form must be dated and retained 
by the Investigator as part of the study records. The Investigator will not undertake any 
investigation specifically required only for the clinical study until valid consent has been 
obtained. The terms of the consent and when it was obtained must also be documented in 
the eCRF. 
If a protocol amendment is required, the ICF may need to be revised to reflect the 
changes to the protocol. If the consent form is revised, it must be reviewed and approved 
by the appropriate IEC/IRB and signed by all patients subsequently enrolled in the study 
as well as those currently enrolled in the study. 
14.3 Protocol Approval and Amendment 
Before the start of the study, the study protocol and/or other relevant documents will be 
approved by the IEC/IRB/Competent Authorities, in accordance with local legal 
requirements. The Sponsor must ensure that all ethical and legal requirements have been 
met before the first patient is enrolled in the study. 
This protocol is to be followed exactly. To alter the protocol, amendments must be 
written, receive approval from the appropriate personnel, and receive 
IRB/IEC/Competent Authority approval prior to implementation (if appropriate).  
Administrative changes (not affecting the patient benefit/risk ratio) may be made without 
the need for a formal amendment. All amendments will be distributed to all protocol 
recipients, with appropriate instructions. 
14.4 Archiving Study Records 
According to ICH guidelines, essential documents should be retained for a minimum of 
2 years after the last approval of a marketing application in an ICH region and until there 
are no pending or contemplated marketing applications in an ICH region or at least 
2 years have elapsed since the formal discontinuation of clinical development of the 
investigational product. However, these documents should be retained for a longer period 
if required by the applicable legal requirements. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
61 
14.5 Premature Termination of the Study 
If the Investigator, the Sponsor, or the Medical Monitor becomes aware of conditions or 
events that suggest a possible hazard to patients if the study continues, the study may be 
terminated after appropriate consultation between the relevant parties. The study may 
also be terminated early at the Sponsor’s discretion in the absence of such a finding. 
Conditions that may warrant termination include, but are not limited to: 
• The discovery of an unexpected, significant, or unacceptable risk to the patients 
enrolled in the study; 
• Failure to enrol patients at an acceptable rate; 
• A decision on the part of the Sponsor to suspend or discontinue development of the 
drug. 
14.6 Confidentiality 
All study findings and documents will be regarded as confidential. The Investigator and 
members of his/her research team must not disclose such information without prior 
written approval from the Sponsor. 
The anonymity of participating patients must be maintained. Patients will be identified on 
eCRFs and other documents submitted to 
 by their patient number, initials 
and/or birth date, not by name. Documents not to be submitted to Pharm-Olam that 
identify the patient (e.g., the signed ICF) must be maintained in confidence by the 
Investigator.  
14.7 Future Use of Stored Specimens 
In order to appropriately assess the incidence of post-operative staphylococcal infections 
investigators will take all reasonable efforts to obtain microbiological documentation and 
a bacterial isolate when the suspicion of a staphylococcal post-operative infection is 
raised. This includes but is not limited to the collection and culture of exudates, blood, 
implant or other specimens according to the suspected site of infection.  
The Sponsor is planning to store these samples as well as those bacterial isolates obtained 
from the nasal swabs after the completion of the study for up to 10 years for further 
analysis and characterization. The details of these tests are not known at this time. No 
subject identifying information will be retained for these samples. The Informed Consent 
Form explains the storage and future use of specimens and subjects will be asked to 
consent for future testing of samples. 
14.8 Liability and Insurance 
The Sponsor will take out reasonable third-party liability insurance cover in accordance 
with all local legal requirements. The civil liability of the Investigator, the persons 
instructed by him and the hospital, practice or institute in which they are employed and 
the liability of the Sponsor with respect to financial loss due to personal injury and other 
damage that may arise as a result of the carrying out of this study are governed by the 
applicable law. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
62 
The Sponsor will arrange for patients participating in this study to be insured against 
financial loss due to personal injury caused by the pharmaceutical products being tested 
or by medical steps taken in the course of the study. 
14.9 Publication Policy 
By signing the study protocol, the Investigator agrees with the use of results of the study 
for the purposes of national and international registration, publication and information for 
medical and pharmaceutical professionals. If necessary, the authorities will be notified of 
the Investigator's name, address, qualifications and extent of involvement. 
An Investigator shall not publish any data (poster, abstract, paper, etc.) without having 
consulted with the Sponsor in advance. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
63 
15 REFERENCE LIST 
1. 
Ooi N, Miller K, Hobbs J, Rhys-Williams W, Love W, Chopra I. XF-73, a novel 
antistaphylococcal membrane-active agent with rapid bactericidal activity. The 
Journal of antimicrobial chemotherapy 2009;64:735-40. 
2. 
Farrell DJ, Robbins M, Rhys-Williams W, Love WG. In vitro activity of XF-73, a 
novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive 
and Gram-negative bacterial species. International journal of antimicrobial 
agents 2010;35:531-6. 
3. 
Farrell DJ, Robbins M, Rhys-Williams W, Love WG. Investigation of the 
potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, 
daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus 
isolates during a 55-passage study. Antimicrobial agents and chemotherapy 
2011;55:1177-81. 
4.  
Holtfreter S, Grumann D, Balau V, et al. Molecular Epidemiology of 
Staphylococcus aureus in the General Population in Northeast Germany: Results 
of the Study of Health in Pomerania (SHIP-TREND-0). Journal of clinical 
microbiology 2016; 54:2774-85. 
5.  
Kim DH, Spencer M, Davidson SM, et al. Institutional pre-screening for detection 
and eradication of methicillin-resistant Staphylococcus aureus in patients 
undergoing elective orthopaedic surgery. The Journal of bone and joint surgery 
American volume 2010; 92:1820-6. 
6.  
Mendy A, Vieira ER, Albatineh AN, Gasana J. Staphylococcus aureus 
Colonization and Long-Term Risk for Death, United States. Emerging infectious 
diseases 2016; 22:1966-9. 
7.  
Sporer SM, Rogers T, Abella L. Methicillin-Resistant and Methicillin-Sensitive 
Staphylococcus aureus Screening and Decolonization to Reduce Surgical Site 
Infection in Elective Total Joint Arthroplasty. The Journal of arthroplasty 2016; 
31:144-7. 
8.  
Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG, Jr. Staphylococcus 
aureus infections: epidemiology, pathophysiology, clinical manifestations, and 
management. Clinical microbiology reviews 2015; 28:603-61. 
9.  
Bertrand X, Slekovec C, Talon D. Use of mupirocin-chlorhexidine treatment to 
prevent Staphylococcus aureus surgical-site infections. Future microbiology 
2010; 5:701-3. 
10.  
von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a 
source of Staphylococcus aureus bacteremia. Study Group. The New England 
journal of medicine 2001; 344:11-6. 
11.  
Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in 
Staphylococcus aureus infections. The Lancet Infectious diseases 2005; 5:751-62. 
12.  
Williams RE. Healthy carriage of Staphylococcus aureus: its prevalence and 
importance. Bacteriological reviews 1963;27:56-71. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
64 
13.  
Sollid JU, Furberg AS, Hanssen AM, Johannessen M. Staphylococcus aureus: 
determinants of human carriage. Infection, genetics and evolution: journal of 
molecular epidemiology and evolutionary genetics in infectious diseases 
2014;21:531-41. 
14.  
VandenBergh MF, Yzerman EP, van Belkum A, Boelens HA, Sijmons M, 
Verbrugh HA. Follow-up of Staphylococcus aureus nasal carriage after 8 years: 
redefining the persistent carrier state. Journal of clinical microbiology 1999; 
37:3133-40. 
15.  
Kluytmans JA, Wertheim HF. Nasal carriage of Staphylococcus aureus and 
prevention of nosocomial infections. Infection 2005; 33:3-8. 
16.  
Perl TM, Golub JE. New approaches to reduce Staphylococcus aureus nosocomial 
infection rates: treating S. aureus nasal carriage. The Annals of pharmacotherapy 
1998; 32: S7-16. 
17.  
Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus 
and the incidence of postoperative wound infection. The Journal of hospital 
infection 1995; 31:13-24. 
18.  
Wertheim HF, Vos MC, Ott A, et al. Risk and outcome of nosocomial 
Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 
(London, England) 2004; 364:703-5. 
19.  
Suaya JA, Mera RM, Cassidy A, O'Hara P, Amrine-Madsen H, Burstin S, Miller 
LG. Incidence and cost of hospitalizations associated with Staphylococcus aureus 
skin and soft tissue infections in the United States from 2001 through 2009. BMC 
infectious diseases 2014; 14:296. 
20.  
Bode LG, Kluytmans JA, Wertheim HF, et al. Preventing surgical-site infections 
in nasal carriers of Staphylococcus aureus. The New England journal of medicine 
2010; 362:9-17. 
21.  
Hebert C, Robicsek A. Decolonization therapy in infection control. Current 
opinion in infectious diseases 2010; 23:340-5. 
22.  
Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of 
health care-associated infections. The New England journal of medicine 2014;3 
70:1198-208. 
23.  
Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR, 
Sievert DM. Antimicrobial-Resistant Pathogens Associated With Healthcare-
Associated Infections: Summary of Data Reported to the National Healthcare 
Safety Network at the Centers for Disease Control and Prevention, 2011-2014. 
Infection control and hospital epidemiology 2016; 37:1288-301. 
24.  
ECDC. Annual Epidemiological Report for 2014 - Antimicrobial Resistance 
(EARS-Net), 2018. 
25.  
Calfee DP, Salgado CD, Milstone AM, et al. Strategies to prevent methicillin-
resistant Staphylococcus aureus transmission and infection in acute care hospitals: 
2014 update. Infection control and hospital epidemiology 2014; 
35 Suppl 2:S108-32. 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
65 
26.  
Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for 
antimicrobial prophylaxis in surgery. American journal of health-system 
pharmacy: AJHP: official. 
27. 
Verhoeven PO, Grattard F, Carricajo A, Lucht F, Cazorla C, Garraud O, Pozzetto 
B, Berthelot P. An algorithm based on one or two nasal samples is accurate to 
identify persistent nasal carriers of Staphylococcus aureus. Clin Microbiol Infect. 
2012 Jun;18(6):551-7. doi: 10.1111/j.1469-0691.2011.03611.x. 
 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
66 
16 APPENDICES 
16.1 List of Organizations Involved in the Study 
Sponsor 
Destiny Pharma plc 
Sussex Innovation Centre 
Science Park Square,  
Falmer 
Brighton, BN1 9SB 
UK 
Chief Medical Monitor 
 
Contract Research 
Organization 
 
 
  
 
 
Safety Reporting 
 
 
 
 
 
 
 
 
 
  
Data Management, Statistics 
and Medical Writing 
 
 
 
 
 
 
 
Central Laboratory 
 
Blood samples, Nasal Swabs and Bacterial Isolate 
storage: 
 
 
 
 
 
 
 
 

Destiny Pharma plc 
Clinical Protocol v2.1 
XF-73B07 
CONFIDENTIAL 
 
67 
 
Nasal Swabs, post-operative infection sample 
processing and bacterial isolate storage: 
 
 
 
 
 
  
 
IP Supply & IRT 
 
  
  
  
  
 
Regulatory Unblinding 
Service